UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act 1934
Date of Report: January 23, 1998
INTEGRAMED AMERICA, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Delaware
- --------------------------------------------------------------------------------
(State of other jurisdiction of incorporation)
0-20260 and 1-11440 06-1150326
- --------------------------------------------------------------------------------
(Commission File Numbers) (IRS Employer Identification No.)
One Manhattanville Road, Purchase, NY 10577
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone no. including area code: (914) 253-8000
<PAGE>
5. Other Events.
On January 23, 1998, IntegraMed America, Inc. (the "Company") entered into
an Investment Agreement with Morgan Stanley Venture Partners III, L.P., Morgan
Stanley Venture Investors III, L.P. and The Morgan Stanley Venture Partners
Entrepreneur Fund, L.P. ("Morgan Stanley") pursuant to which the Company sold to
Morgan Stanley for a total purchase price of $5,500,000 an aggregate of
3,235,294 shares of its Common Stock, $.01 par value per share ("Common Stock")
and warrants expiring January 23, 2002 to purchase 240,000 shares of Common
Stock, at an exercise price of $.01 per share (the "Warrants"). Morgan Stanley
was granted registration rights with respect to the shares of Common Stock sold
pursuant to the Investment Agreement and the shares of Common Stock issuable
upon exercise of the Warrants. Morgan Stanley also has the right to designate
nominees for election to the Company's Board of Directors based on its
proportionate voting interest in the Company. In addition, Morgan Stanley is
required to vote all of its voting securities for nominees to the Company's
Board of Directors who have been recommended by the Company's Board of
Directors.
In addition, the Company entered into a letter of intent with respect to the
purchase by the Company of Shady Grove Fertility Centers, Inc. and a long term
management agreement with its shareholders.
Reference is made to the press release of the Registrant dated January 26,
1998 filed as exhibit 99.1 hereto and incorporated by reference herein.
Exhibit No. Description of Exhibit
----------- ----------------------
4.6 Warrant issued to Morgan Stanley Venture Partners III, L.P.
4.7 Warrant issued to Morgan Stanley Venture Partners III, L.P.
4.8 Warrant issued to The Morgan Stanley Venture Partners
Entrepreneur Fund, L.P.
10.92 Investment Agreement between Registrant and Morgan Stanley
Venture Partners III, L.P., Morgan Stanley Venture Investors
III, L.P. and the Morgan Stanley Venture Partners
Entrepreneur Fund, L.P., including exhibits thereto.
99.1 Press Release of Registrant dated January 26, 1998.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INTEGRAMED AMERICA, INC.
(Registrant)
Date: February 12, 1998 By: /s/ Dwight P. Ryan
------------------
Dwight P. Ryan
Vice President and
Chief Financial Officer
(Principal Financial and
Accounting Officer)
CONFORMED COPY
INVESTMENT AGREEMENT
dated as of
January 23, 1998
among
MORGAN STANLEY VENTURE PARTNERS III, L.P.,
MORGAN STANLEY VENTURE INVESTORS III, L.P.,
THE MORGAN STANLEY VENTURE PARTNERS
ENTREPRENEUR FUND, L.P.,
and
INTEGRAMED AMERICA, INC.
<PAGE>
TABLE OF CONTENTS
----------------------
PAGE
ARTICLE 1
DEFINITIONS
SECTION 1.01. Definitions..................................................1
ARTICLE 2
PURCHASE AND SALE
SECTION 2.01. Purchase and Sale............................................5
SECTION 2.02. Closing......................................................5
SECTION 2.03. Legending of Securities......................................5
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
SECTION 3.01. Corporate Existence and Power................................6
SECTION 3.02. Corporate Authorization......................................6
SECTION 3.03. Governmental Authorization...................................7
SECTION 3.04. Non-contravention............................................7
SECTION 3.05. Capitalization...............................................7
SECTION 3.06. Subsidiaries.................................................8
SECTION 3.07. SEC Filings..................................................8
SECTION 3.08. Financial Statements.........................................9
SECTION 3.09. Absence of Certain Changes...................................9
SECTION 3.10. No Undisclosed Material Liabilities..........................10
SECTION 3.11. Litigation...................................................11
SECTION 3.12. Compliance with Laws.........................................11
SECTION 3.13. Finders' Fees................................................11
SECTION 3.14. Employee Benefit Plans.......................................11
SECTION 3.15. Taxes........................................................12
SECTION 3.16. Environmental Matters........................................13
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF THE FUNDS
SECTION 4.01. Organization.................................................15
SECTION 4.02. Power and Authorization......................................15
SECTION 4.03. Governmental Authorization...................................15
SECTION 4.04. Non-contravention............................................15
SECTION 4.05. Finders' Fees................................................15
SECTION 4.06. Purchase for Investment......................................16
SECTION 4.07. Disclosure of Information....................................16
<PAGE>
PAGE
SECTION 4.08. Restricted Securities........................................16
ARTICLE 5
COVENANTS OF THE COMPANY
SECTION 5.01. Notices of Certain Events....................................16
SECTION 5.02. Registration Rights..........................................17
SECTION 5.03. Access to Book and Records...................................17
ARTICLE 6
COVENANTS OF THE FUNDS
SECTION 6.01. Notices of Certain Events....................................17
SECTION 6.02. Agreement to Provide Information.............................17
ARTICLE 7
COVENANTS OF THE COMPANY AND THE FUNDS
SECTION 7.01. Filings; Consents............................................18
ARTICLE 8
ADDITIONAL COVENANTS
SECTION 8.01. Board Representation; Committees.............................18
SECTION 8.02. Reports......................................................18
SECTION 8.03. Pre-emptive Rights...........................................19
SECTION 8.04. Voting Arrangements..........................................20
ARTICLE 9
TERMINATION
SECTION 9.01. Grounds for Termination......................................20
SECTION 9.02. Effect of Termination........................................20
ARTICLE 10
MISCELLANEOUS
SECTION 10.01. Notices.....................................................21
SECTION 10.02. Survival....................................................22
SECTION 10.03. Amendments and Waivers......................................22
SECTION 10.04. Expenses....................................................22
SECTION 10.05. Successors and Assigns......................................23
<PAGE>
PAGE
SECTION 10.06. Governing Law...............................................23
SECTION 10.07. Counterparts; Third Party Beneficiaries.....................23
SECTION 10.08. Public Announcements........................................23
SECTION 10.09. Entire Agreement; Exhibits..................................23
SECTION 10.10. Headings....................................................23
Exhibit A Registration Rights Agreement
Exhibit B Form of Warrant
<PAGE>
INVESTMENT AGREEMENT
AGREEMENT dated as of January 23, 1998 among Morgan Stanley Venture
Partners III, L.P., a Delaware limited partnership ("MSVP III Fund"), Morgan
Stanley Venture Investors III, L.P., a Delaware limited partnership ("Employee
Fund") and The Morgan Stanley Venture Partners Entrepreneur Fund, L.P., a
Delaware limited partnership ("Entrepreneur Fund") and IntegraMed America, Inc.,
a Delaware corporation (the "Company").
The parties hereto agree as follows:
ARTICLE 1
DEFINITIONS
SECTION 1.01. Definitions. (a) The following terms, as used herein,
have the following meanings:
"1933 Act" means the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder.
"1934 Act" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.
"Affiliate" means, with respect to any Person, any other Person
directly or indirectly controlling, controlled by, or under common control with
such Person.
"Balance Sheet" means the audited consolidated balance sheet of the
Company and the Subsidiaries as of December 31, 1996.
"Balance Sheet Date" means December 31, 1996.
"beneficial ownership" and "beneficially own" shall be determined in
accordance with Rules 13d-3 and 13d-5 under the 1934 Act.
"Benefit Arrangement" means any employment, severance or similar
contract or arrangement (whether or not written) or any plan, policy, fund,
program or contract or arrangement (whether or not written) providing for
compensation, bonus, profit-sharing, stock option, or other stock related rights
or other forms of incentive or deferred compensation, vacation benefits,
insurance coverage (including any self-insured arrangements), health or medical
benefits, disability benefits, worker's compensation, supplemental unemployment
benefits, severance benefits and post-employment or retirement benefits
(including compensation, pension, health, medical or life insurance or other
benefits) that (i) is not an Employee Plan, (ii) is entered into, maintained,
administered or contributed to, as the case may be, by the Company or any of its
Affiliates and (iii) covers any employee or former employee of the Company or
any Subsidiary of the Company.
1
<PAGE>
"Closing Date" means the date of the Closing.
"Code" means the United States Internal Revenue Code of 1986, as
amended.
"Commission" means the United States Securities and Exchange
Commission.
"Common Stock" means the Common Stock of the Company, par value $.01
per share.
"Common Stock Plan" means any present or future Employee Plan,
employment agreement, restricted stock, stock option, stock purchase or dividend
reinvestment plan or other similar type of plan or arrangement of the Company
which provides for the issuance of equity securities or options or rights to
purchase equity securities of the Company.
"Convertible Securities" means any securities convertible into or
exercisable for Voting Securities.
"Employee Plan" means any "employee benefit plan", as defined in
Section 3(3) of ERISA, that (i) is subject to any provision of ERISA, (ii) is
maintained, administered or contributed to by the Company or any of its
Affiliates and (iii) covers any employee or former employee of the Company or
any Subsidiary of the Company.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended, and any successor statute thereto, and the rules and regulations
promulgated thereunder.
"ERISA Affiliate" of any entity means any other entity which, together
with such entity, would be treated as a single employer under Section 414 of the
Code.
"Fund" means each or any of the MSVP III Fund, the Employee Fund and
the Entrepreneur Fund.
"Lien" means, with respect to any property or asset, any mortgage,
lien, pledge, charge, security interest, encumbrance or other adverse claim of
any kind in respect of such property or asset. For the purposes of this
Agreement, a Person shall be deemed to own subject to a Lien any property or
asset which it has acquired or holds subject to the interest of a vendor or
lessor under any conditional sale agreement, capital lease or other title
retention agreement relating to such property or asset.
2
<PAGE>
"Material Adverse Effect" means a material adverse effect on the
condition (financial or otherwise), business, assets or results of operations of
the Company and the Subsidiaries, taken as a whole.
"MSVP" means the program of investment funds comprising the MSVP III
Fund, the Employee Fund and the Entrepreneur Fund.
"Multiemployer Plan" means a multiemployer plan, as defined in Section
3(37) of ERISA.
"PBGC" means the Pension Benefit Guaranty Corporation.
"Person" means an individual, corporation, partnership, limited
liability company, association, trust or other entity or organization, including
a government or political subdivision or an agency or instrumentality thereof.
"Registration Rights Agreement" means the Registration Rights Agreement
among the parties hereto attached as Exhibit A hereto.
"Restricted Securities" means the shares of Common Stock and any other
securities or rights convertible into or exercisable (whether immediately or
otherwise) for such Common Stock, including the Warrants, in each case purchased
by the Funds pursuant to this Agreement.
"Subsidiary" means any entity of which securities or other ownership
interests having ordinary voting power to elect a majority of the board of
directors or other persons performing similar functions are at the time directly
or indirectly owned by the Company.
"Tax" (and, with correlative meaning, "Taxes" and "Taxable") means (i)
any net income, alternative or add-on minimum tax, gross income, gross receipts,
sales, use, ad valorem, value added, transfer, franchise, profits, license,
withholding on amounts paid to or by any Person, payroll, employment, excise,
severance, stamp, occupation, premium, property, environmental or windfall
profit tax, custom, duty or other tax, governmental fee or other like assessment
or charge of any kind whatsoever, together with any interest or any penalty,
addition to tax or additional amount imposed by any governmental authority (a
"Taxing authority") responsible for the imposition of any such tax (domestic or
foreign), (ii) liability of any Person for the payment of any amounts of the
type described in (i) as a result of being a member of any affiliated,
consolidated, combined or unitary group or being a party to any agreement or
arrangement whereby liability of a Person for payments of such amounts was
determined or taken into account with reference to the liability of any other
Person for any period, and (iii) liability of any Person for the payment of any
amounts of the type described in (i) as a result of any express or implied
obligation to indemnify any other Person.
3
<PAGE>
"Total Voting Power" means the aggregate number of votes which may be
cast by holders of outstanding Voting Securities.
"Voting Securities" means all securities of the Company entitled, in
the ordinary course, to vote in the election of Directors of the Company.
"Warrants" means the 240,000 warrants of the Company, substantially in
the form of Exhibit B hereto, to purchase shares of Common Stock to be issued to
the Funds hereunder.
(b) Each of the following terms is defined in the Section set forth
opposite such term:
Term Section
---- -------
Accredited Investor 4.06
-------
Company Securities 3.05(b)
-------
Closing 2.02
-------
Company 10-K 3.07(a)
-------
Company 10-Q 3.07(a)
-------
Fund Nominee 8.01(a)
-------
Pre-emptive Rights Notice 8.03
-------
Proxy Materials 3.07
-------
Purchase Price 2.01
-------
Shares 2.01
-------
Subsidiary Securities 3.06(b)
-------
ARTICLE 2
PURCHASE AND SALE
SECTION 2.01. Purchase and Sale. Upon the terms and subject to the
conditions of this Agreement, the Company agrees to sell and the Funds agree to
purchase from the Company for an aggregate purchase price of $5,500,000 (the
"Purchase Price") (a) 3,235,294 shares of Common Stock (the "Shares") and (b)
the Warrants. The actual number of Shares and Warrants that each Fund will
purchase shall be determined by the Funds at Closing.
4
<PAGE>
The Purchase Price shall be paid in accordance with Section 2.02.
SECTION 2.02. Closing. The closing (the "Closing") of the transactions
contemplated hereby shall take place at the offices of Davis Polk & Wardwell in
New York City at 1:00 p.m. EST on January 23, 1998 or at such other time or
place as the parties may agree. At the Closing:
(a) The Company shall deliver to each Fund (i) one or more certificates
for the Shares, registered in the name of such Fund and representing the number
of the Shares to be purchased by such Fund and (ii) one or more certificates for
the Warrants, registered in the name of such Fund and representing the number of
the Warrants to be purchased by such Fund; and
(b) Each Fund shall deliver to the Company an amount equal to the
number of the Shares to be purchased by such Fund at the Closing multiplied by
$1.70 per share for an aggregate amount equal to the Purchase Price in
immediately available funds by wire transfer to an account of the Company
designated by the Company, by notice to each Fund, no later than two business
days prior to the Closing.
SECTION 2.03. Legending of Securities. All securities to be issued to
each Fund by the Company hereunder shall bear the following legend:
"The securities represented hereby have not been registered under the
Securities Act of 1933, as amended, or securities laws of any state and
may not be offered, sold, transferred or otherwise disposed of except
in compliance therewith."
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to each Fund as of the date hereof
and as of the Closing Date that:
SECTION 3.01. Corporate Existence and Power. The Company is a
corporation duly incorporated, validly existing and in good standing under the
laws of its jurisdiction of incorporation and has all corporate powers and all
governmental licenses, authorizations, permits, consents and approvals required
to carry on its business as now conducted, except for those licenses,
authorizations, permits, consents and approvals the absence of which would not,
individually or in the aggregate, have a Material Adverse Effect. The Company is
duly qualified to do business as a foreign corporation and is in good standing
in each jurisdiction where such qualification is necessary, except for those
jurisdictions where failure to be so qualified or in good standing would not,
individually or in the aggregate, have a Material Adverse Effect. The Company
has heretofore delivered to each Fund true and complete copies of the
certificate of incorporation and bylaws of the Company as currently in effect.
5
<PAGE>
SECTION 3.02. Corporate Authorization. (a) The execution, delivery and
performance by the Company of this Agreement are within the Company's corporate
powers and have been duly authorized by all necessary corporate action on the
part of the Company. This Agreement constitutes a valid and binding agreement of
the Company enforceable against the Company in accordance with its terms, except
as the indemnification under the Registration Rights Agreement may be limited by
applicable law and except as the enforcement hereof may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
relating to or affecting creditors' rights generally and by equitable
principles.
(b) The Shares, when issued and delivered to and paid for by each Fund
pursuant to this Agreement, will be validly issued, fully paid and
non-assessable, and the issuance of such Shares is not subject to any preemptive
or similar rights, except as set forth in this Agreement. The shares of Common
Stock reserved for issuance upon exercise of the Warrants have been duly
authorized by the Company and reserved for issuance upon such exercise and, when
issued upon such exercise in accordance with the terms of the Warrants, will
have been validly issued, fully paid and non-assessable, and such shares of
Common Stock will be free of preemptive rights or similar rights except as set
forth in this Agreement.
(c) The Warrants, when executed and delivered in accordance with the
terms of this Agreement, will constitute a valid and binding obligation of the
Company.
SECTION 3.03. Governmental Authorization. The execution, delivery and
performance by the Company of this Agreement and the Warrants require no action
by or in respect of, or filing with, any governmental body, agency, or official
other than (i) compliance with any applicable requirements of the 1934 Act; (ii)
compliance with any applicable existing requirements of the Nasdaq Stock Market;
and (iii) any action or filing as to which the failure to make or obtain would
not, individually or in the aggregate, have a Material Adverse Effect.
SECTION 3.04. Non-contravention. The execution, delivery and
performance by the Company of this Agreement and the Warrants do not and will
not (i) violate the certificate of incorporation or bylaws of the Company or any
Subsidiary; (ii) assuming compliance with the matters referred to in Section
3.03, violate any applicable law, rule, regulation, judgment, injunction, order
or decree; (iii) constitute a default under, or give rise to any right of
termination, cancellation or acceleration of any right or obligation of the
Company or any Subsidiary or to a loss of any benefit to which the Company or
any Subsidiary is entitled under, any agreement or other instrument binding upon
the Company or any Subsidiary or any license, franchise, permit or other similar
authorization held by the Company or any Subsidiary; or (iv) result in the
creation or imposition of any material Lien on any asset of the Company or any
Subsidiary.
6
<PAGE>
SECTION 3.05. Capitalization. (a) The authorized capital stock of the
Company consists of (i) 25,000,000 shares of Common Stock, of which 17,432,730
shares are issued and outstanding as of January 15, 1998, (ii) 3,165,644 shares
of preferred stock, $1.00 par value, of which: (A) 2,500,000 shares are
undesignated; (B) 665,644 shares are designated as Series A Cumulative
Convertible of which 165,644 were issued or outstanding as of January 15, 1998;
(iii) warrants outstanding to purchase 775,427 shares of Common Stock as of
January 15, 1998; and (iv) options outstanding to purchase 1,420,602 shares of
Common Stock as of January 15, 1998 (including a grant of options to purchase
175,000 shares of Common Stock which is subject to stockholder approval
increasing the number of shares authorized under the plan). All outstanding
shares of Common Stock and any other class of capital stock of the Company have
been duly authorized and are validly issued, fully paid and nonassessable.
(b) Except as set forth in Section 3.05(a), there are no outstanding
(i) shares of capital stock or Voting Securities of the Company, (ii) securities
of the Company convertible into or exchangeable for shares of capital stock or
Voting Securities of the Company or (iii) except as set forth on Schedule
3.05(b), warrants, options or other rights to acquire from the Company, or other
obligations of the Company to issue, any capital stock, Voting Securities or
securities convertible into or exchangeable for capital stock or Voting
Securities of the Company (the items in clauses 3.05(b)(i), (ii) and (iii) being
referred to collectively as the "Company Securities"). There are no outstanding
obligations of the Company or any Subsidiary to repurchase, redeem or otherwise
acquire any Company Securities.
SECTION 3.06. Subsidiaries. (a) Each Subsidiary is a corporation duly
incorporated, validly existing and in good standing under the laws of its
jurisdiction of incorporation, has all corporate powers and all governmental
licenses, authorizations, permits, consents and approvals required to carry on
its business as now conducted, except for those licenses, authorizations,
permits, consents and approvals the absence of which would not, individually or
in the aggregate, have a Material Adverse Effect, is duly qualified to do
business as a foreign corporation and is in good standing in each jurisdiction
where such qualification is necessary, except for those jurisdictions where the
failure to be so qualified or in good standing would not, individually or in the
aggregate, have a Material Adverse Effect. All Subsidiaries and their respective
jurisdictions of incorporation are identified on Schedule 3.06(a).
7
<PAGE>
(b) Except as set forth on Schedule 3.06(b), all of the outstanding
capital stock of, or other voting securities or ownership interests in, each
Subsidiary, is owned by the Company, directly or indirectly, free and clear of
any Lien and free of any other limitation or restriction (including any
restriction on the right to vote, sell or otherwise dispose of such capital
stock or other voting securities or ownership interests). There are no
outstanding (i) securities of the Company or any Subsidiary convertible into or
exchangeable for shares of capital stock or other voting securities or ownership
interests in any Subsidiary or (ii) options or other rights to acquire from the
Company or any Subsidiary, or other obligation of the Company or any Subsidiary
to issue, any capital stock or other voting securities or ownership interests
in, or any securities convertible into or exchangeable for any capital stock or
other voting securities or ownership interests in, any Subsidiary (the items in
clauses 3.06(b)(i) and (ii) being referred to collectively as the "Subsidiary
Securities").
SECTION 3.07. SEC Filings. (a) The Company has delivered to each Fund
(i) the annual report on Form 10-K for its fiscal year ended December 31, 1996
(the "Company 10-K"), (ii) its quarterly report on Form 10-Q for its fiscal
quarters ended March 31, June 30, and September 30, 1997 (each, a "Company
10-Q"), (iii) its proxy or information statements relating to meetings of, or
actions taken without a meeting by, the stockholders of the Company since
January 1, 1997 (the "Proxy Materials") and (iv) all of its other reports,
statements, schedules and registration statements filed with the Commission
since January 1, 1997 (the items in clauses 3.07(a)(i) through (iv) being
referred to collectively as the "SEC Reports").
(b) As of its filing date, or, if such SEC Report was amended, on the
date of filing of such amendment, each SEC Report did not contain any untrue
statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading.
SECTION 3.08. Financial Statements. The audited consolidated balance
sheets as of December 31, 1995 and 1996 and the related audited consolidated
statements of operations and cash flows for each of the years ended December 31,
1995 and 1996 included in the Company 10-K and the unaudited interim
consolidated balance sheet as of September 30, 1997 and the related unaudited
interim consolidated statements of operations and cash flows for the three
months ended September 30, 1997 included in the Company 10-Q, of the Company
fairly present, in conformity with generally accepted accounting principles
applied on a consistent basis (except as may be indicated in the notes thereto),
the consolidated financial position of the Company as of the dates thereof and
its consolidated results of operations and cash flows for the periods then ended
(subject to normal year-end adjustments in the case of any unaudited interim
financial statements).
8
<PAGE>
SECTION 3.09. Absence of Certain Changes. Since the Balance Sheet Date
other than as disclosed, or provided for, in the Company 10-K, a Company 10-Q or
other SEC Report and except as set forth in Schedule 3.09, the businesses of the
Company and its Subsidiaries have been conducted in the ordinary course
consistent with past practices and there has not been:
(a) any event, occurrence, development or state of circumstances or
facts which has had or would reasonably be expected to have a Material Adverse
Effect;
(b) any declaration, setting aside or payment of any dividend or other
distribution with respect to any shares of capital stock of the Company, or any
repurchase, redemption or other acquisition by the Company or any Subsidiary of
any outstanding shares of capital stock or other securities of, or other
ownership interests in, the Company or any Subsidiary;
(c) any amendment of any material term of any outstanding security of
the Company or any Subsidiary;
(d) any incurrence, assumption or guarantee by the Company or any
Subsidiary of any indebtedness for borrowed money, except in the ordinary course
of business consistent with past practices;
(e) any creation or assumption by the Company or any Subsidiary of any
Lien on any material asset other than in the ordinary course of business
consistent with past practices;
(f) any making of any loan, advance or capital contributions to or
investment in any Person other than loans, advances or capital contributions to
or investments in Subsidiaries made in the ordinary course of business
consistent with past practices;
(g) any damage, destruction or other casualty loss (whether or not
covered by insurance) affecting the business or assets of the Company or any
Subsidiary which, individually or in the aggregate, has had or would reasonably
be expected to have a Material Adverse Effect;
(h) any change in any method of accounting or application thereof by
the Company or any Subsidiary, except for any such change required by reason of
a concurrent change in generally accepted accounting principles;
9
<PAGE>
(i) any (A) employment, deferred compensation, severance, retirement
or other similar agreement entered into with any director, officer or employee
of the Company or any Subsidiary (or any amendment to any such existing
agreement), (B) grant of any severance or termination pay to any director,
officer or employee of the Company or any Subsidiary, or (C) change in
compensation or other benefits payable to any director, officer or employee of
the Company or any Subsidiary pursuant to any severance or retirement plans or
policies thereof, other than in the ordinary course of business consistent with
past practices; or
(j) any labor dispute, other than routine individual grievances, or
any activity or proceeding by a labor union or representative thereof to
organize any employees of the Company or any Subsidiary, which employees were
not subject to a collective bargaining agreement at December 31, 1996, or any
lockouts, strikes, slowdowns, work stoppages or threats thereof by or with
respect to any employees of the Company or any Subsidiary.
SECTION 3.10. No Undisclosed Material Liabilities. Except as set forth
on Schedule 3.10, there are no liabilities of the Company or any Subsidiary of
any kind whatsoever, whether accrued, contingent, absolute, determined,
determinable or otherwise, and there is no existing condition, situation or set
of circumstances which could reasonably be expected to result in such a
liability, other than:
(a) liabilities disclosed or provided for in the Balance Sheet;
(b) liabilities incurred in the ordinary course of business consistent
with past practice since the Balance Sheet Date, which in the aggregate are not
material, except for liabilities incurred in connection with normal and
recurring fourth quarter operations, to the Company and the Subsidiaries, taken
as a whole; and
(c) liabilities under this Agreement.
SECTION 3.11. Litigation. Except as set forth on Schedule 3.11, there
is no action, suit, investigation or proceeding pending against, or to the
knowledge of the Company threatened against or affecting, the Company or any
Subsidiary or any of their respective properties before any court or arbitrator
or any governmental body, agency or official (i) which would reasonably be
expected to have a Material Adverse Effect or (ii) which in any manner
challenges or seeks to prevent, enjoin, alter or materially delay the
transactions contemplated by this Agreement.
SECTION 3.12. Compliance with Laws. Neither the Company nor any
Subsidiary is in violation of or has violated any applicable law, rule or
regulation, except for violations which individually or in the aggregate would
not reasonably be expected to have a Material Adverse Effect.
10
<PAGE>
SECTION 3.13. Finders' Fees. There is no investment banker, broker,
finder or other intermediary which has been retained by or is authorized to act
on behalf of the Company who might be entitled to any fee or commission in
connection with the transactions contemplated by this Agreement.
SECTION 3.14. Employee Benefit Plans. (a) The Company has provided
the Funds with a list identifying each Employee Plan and Benefit Arrangement.
(b) No Employee Plan (i) constitutes a Multiemployer Plan or (ii) is
maintained in connection with any trust described in Section 501(c)(9) of the
Code. Neither the Company nor any ERISA Affiliate of the Company maintains,
contributes to, or is required to contribute to nor in the past has maintained,
contributed to or been required to contribute to any plan subject to Title IV of
ERISA.
(c) Each Employee Plan which is intended to be qualified under Section
401(a) of the Code is so qualified and has been so qualified during the period
from its adoption to date, and each trust forming a part thereof is exempt from
tax pursuant to Section 501(a) of the Code and has been so exempt since its
creation. The Company has furnished to the Funds copies of the most recent
Internal Revenue Service determination letter with respect to each such Employee
Plan. To the Company's knowledge, each Employee Plan and Benefit Arrangement has
been maintained in substantial compliance with its terms and with the
requirements prescribed by any and all statutes, orders, rules and regulations,
including but not limited to ERISA and the Code, which are applicable to such
Employee Plan or Benefit Arrangement, as applicable.
(d) Except as disclosed in Schedule 3.14, there is no contract,
agreement, plan or arrangement covering any employee or former employee of the
Company or any Subsidiary that, individually or collectively, could give rise to
the payment of any amount that would not be deductible pursuant to the terms of
Sections 162(m) or 280G of the Code.
(e) Neither the Company nor any Subsidiary maintains or contributes to
any Employee Plan which provides, or has any liability to provide life
insurance, medical or other welfare benefits to any employee upon retirement or
termination of employment, except as may be required by law.
(f) Except as disclosed in writing to the Funds since the Balance Sheet
Date, there has been no amendment to, written interpretation or announcement
(whether or not written) by the Company or any of its affiliates relating to, or
11
<PAGE>
change in employee participation or coverage under, any Employee Plan or Benefit
Arrangement which would increase materially the expense of maintaining such
Employee Plan or Benefit Arrangement above the level of the expense incurred in
respect thereof for the fiscal year ended on the Balance Sheet Date.
(g) Except as set forth in Schedule 3.14 or disclosed in the Company's
SEC Reports, neither the Company nor any Subsidiary is a party to or subject to
any union contract or any employment contract providing for annual future
compensation of $100,000 or more with any officer, consultant, director or
employee.
SECTION 3.15. Taxes. Except as disclosed in the financial statements
included in the Company 10-K (including the notes thereto) or except as
disclosed on Schedule 3.15 or except in respect of Taxes, the liability for
which would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, (i) all Tax returns, statements, reports and
forms required to be filed with any Taxing authority by or on behalf of the
Company or any Subsidiary (collectively, the "Returns"), on or prior to the
Closing Date have been or will be filed when due in accordance with all
applicable laws except where failure to so file would not subject the Company or
any Subsidiary to liabilities or penalties; (ii) as of the time of filing, the
Returns correctly reflected (and, as to any Returns not filed as of the date
hereof, will correctly reflect) the facts regarding the income, business,
assets, operations, activities and status of the Company and each Subsidiary;
(iii) the Company and each Subsidiary has timely paid, withheld or made
provision for all Taxes shown as due and payable on the Returns that have been
filed; (iv) neither the Company nor any Subsidiary is delinquent in the payment
of any Tax and has not requested any extension of time within which to file or
send any Return, which Return has not since been filed or sent; (v) neither the
Company nor any Subsidiary (or any member of any affiliated or combined group of
which the Company or any Subsidiary is or has been a member) has been granted
any extension or waiver of the limitation period applicable to the assessment or
collection of any Taxes payable by the Company or any Subsidiary which will
remain in effect after the Closing Date; (vi) there is no claim, audit, action,
suit, proceeding or investigation now pending or threatened against or with
respect to the Company or any Subsidiary of which the Company is aware in
respect of any Tax or assessment; and (vii) there are no liens for Taxes upon
the assets of the Company or any Subsidiary except liens for current Taxes not
yet due.
SECTION 3.16. Environmental Matters. (a) Except as set forth in the
Company 10-K, a Company 10-Q or other SEC Report or except as disclosed on
Schedule 3.16:
12
<PAGE>
(i) no notice, notification, demand, request for information,
citation, summons or order has been received, no complaint has been
filed, no penalty has been assessed, no investigation, action, claim,
suit, proceeding or review is pending, or, to the knowledge of the
Company or any Subsidiary, threatened by any governmental entity or
other Person with respect to any matters relating to the Company or any
Subsidiary and relating to or arising out of any Environmental Law
which, individually or in the aggregate, could reasonably be expected
to result in a Material Adverse Effect;
(ii) the Company is in compliance with all Environmental Laws and
has, and is in compliance with, all environmental permits, except where
any noncompliance or failure to receive environmental permits could not
reasonably be expected to result in a Material Adverse Effect; and
(iii) to the Company's knowledge, there are no liabilities of, or
relating to, the Company or any Subsidiary of any kind whatsoever,
whether accrued, contingent, absolute, determined, determinable or
otherwise, arising under or relating to any Environmental Law which,
individually or in the aggregate, would reasonably be expected to have
a Material Adverse Effect, and there are no facts, conditions,
situations or set of circumstances which could reasonably be expected
to result in or be the basis for any such liability.
(b) There has been no environmental investigation, study, audit, test,
review or other analysis conducted of which the Company has knowledge in
relation to the current or prior business of the Company or any property or
facility now or previously owned or leased by the Company or any Subsidiary.
(c) Neither the Company nor any Subsidiary owns or leases or has owned
or leased any real property, or conducts or has conducted any operations, in New
Jersey or Connecticut.
(d) For purposes of this Section, the following terms shall have the
meanings set forth below:
(i) "Company" and "Subsidiary" shall include any entity which is,
in whole or in part, a predecessor of the Company or any Subsidiary;
(ii) "Environmental Laws" means any and all federal, state, local
and foreign statutes, laws, judicial decisions, regulations,
ordinances, rules, judgments, orders, decrees, codes, plans,
injunctions, permits, concessions, grants, franchises, licenses,
agreements and governmental restrictions, relating to human health, the
environment or to emissions, discharges or releases of pollutants,
contaminants or other hazardous substances or wastes into the
environment, including without limitation ambient air, surface water,
ground water or land, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport
or handling of pollutants, contaminants or other hazardous substances
or wastes or the clean-up or other remediation thereof;
13
<PAGE>
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF THE FUNDS
Each Fund represents and warrants to the Company, severally as to
itself and not jointly, as of the date hereof and as of the Closing Date that:
SECTION 4.01. Organization. Such Fund is organized under the laws of
the State of Delaware.
SECTION 4.02. Power and Authorization. The execution, delivery and
performance by such Fund of this Agreement are within the powers of such Fund
and have been duly authorized by all necessary action on the part of such Fund.
This Agreement constitutes a valid and binding agreement of such Fund
enforceable against such Fund in accordance with its terms, except as the
indemnification under the Registration Rights Agreement may be limited by
applicable law and except as the enforcement hereof may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
relating to or affecting creditors' rights generally and by equitable
principles.
SECTION 4.03. Governmental Authorization. The execution, delivery and
performance by such Fund of this Agreement require no action by or in respect
of, or filing with, any governmental body, agency or official other than any
such action or filing as to which the failure to make or obtain would not,
individually or in the aggregate, have a material adverse effect on the
condition (financial or otherwise), business, assets or results of operations of
such Fund.
SECTION 4.04. Non-contravention. The execution, delivery and
performance by such Fund of this Agreement do not and will not (i) violate the
certificate or agreement of limited partnership of such Fund or (ii) assuming
compliance with the matters referred to in Section 4.03, violate (x) any
applicable law, rule or regulation, that, in the experience of such Fund, is
normally applicable to general business entities in relation to transactions of
the type contemplated by this Agreement or (y) any judgment, injunction, order
or decree binding on such Fund.
14
<PAGE>
SECTION 4.05. Finders' Fees. There is no investment banker, broker,
finder or other intermediary which has been retained by or is authorized to act
on behalf of such Fund who might be entitled to any fee or commission from such
Fund or any of its Affiliates upon consummation of the transactions contemplated
by this Agreement.
SECTION 4.06. Purchase for Investment. Such Fund is acquiring the
Shares and Warrants for investment for its own account and not with a view to,
or for sale in connection with, any distribution thereof. Such Fund is an
"Accredited Investor" as such term is defined in Regulation D under the 1933
Act.
SECTION 4.07. Disclosure of Information. Each Fund believes it has
received all the information it considers necessary or appropriate for deciding
whether to purchase the Restricted Securities. Each Fund further represents that
it has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the sale of the Restricted Securities.
SECTION 4.08. Restricted Securities. Each Fund understands that the
Restricted Securities it is purchasing are characterized as "restricted
securities" under the federal securities laws inasmuch as they are being
acquired from the Company in a transaction not involving a public offering and
that under such laws and applicable regulations such securities may be resold
without registration under the 1933 Act, only in certain limited circumstances.
In this connection each Fund represents that it is familiar with Rule 144 under
the 1933 Act, as presently in effect, and understands the resale limitations
imposed thereby and by the 1933 Act.
ARTICLE 5
COVENANTS OF THE COMPANY
The Company agrees that:
SECTION 5.01. Notices of Certain Events. The Company shall promptly
notify each Fund of:
(a) any notice or other communication from any Person alleging that the
consent of such Person is or may be required in connection with the transactions
contemplated by this Agreement;
15
<PAGE>
(b) any notice or other communication from any governmental or
regulatory agency or authority in connection with the transactions contemplated
by this Agreement; and
(c) any actions, suits, claims, investigations or proceedings commenced
or to its knowledge threatened against, relating to or involving or otherwise
affecting the Company or any Subsidiary that, if pending on the date of this
Agreement, would have been required to have been disclosed pursuant to Section
3.11.
SECTION 5.02. Registration Rights. At any time after the first
anniversary of the Closing Date, each Fund shall have the registration rights
set forth in Exhibit A.
SECTION 5.03. Access to Book and Records. The Company agrees that,
after Closing and for so long as the Funds in the aggregate beneficially own
directly or indirectly at least 5% of the outstanding shares of Common Stock,
each Fund will have access on reasonable terms to the books, records and
employees of the Company and its Subsidiaries and to the provision by the
Company of all information reasonably requested by such Fund, subject to
confidentiality obligations that at the time may be owed by the Company to third
parties, to appropriate confidentiality arrangements and requirements of law.
ARTICLE 6
COVENANTS OF THE FUNDS
Each Fund agrees that:
SECTION 6.01. Notices of Certain Events. Such Fund shall promptly
notify the Company of:
(a) any notice or other communication from any Person alleging that the
consent of such Person is or may be required in connection with the transactions
contemplated by this Agreement; and
(b) any notice or other communication from any governmental or
regulatory agency or authority in connection with the transactions contemplated
by this Agreement.
SECTION 6.02. Agreement to Provide Information. Such Fund agrees to
provide to the Company in writing all information concerning such Fund as may be
reasonably necessary for the Company to prepare the Proxy Material and any other
current or future securities or regulatory reports or filings of the Company.
16
<PAGE>
ARTICLE 7
COVENANTS OF THE COMPANY AND THE FUNDS
The parties hereto agree that:
SECTION 7.01. Filings; Consents. Each party hereto agrees to cooperate
with each other in good faith and to use its reasonable best efforts in making
all required governmental filings and obtaining at the earliest practicable date
all necessary approvals and consents from governmental entities and third
parties.
ARTICLE 8
ADDITIONAL COVENANTS
SECTION 8.01. Board Representation; Committees. (a) The Company agrees
that MSVP III Fund shall have the right to cause the Company to include, as a
nominee for the Company's Board of Directors recommended by the Board, a number
of Directors (rounded down to the next whole number if the fraction referred to
below is less than one-half or, if otherwise, rounded up to the next whole
number) that is equal to the product of the total number of Directors on the
Board of Directors times a fraction the numerator of which is the aggregate
number of Voting Securities owned by the Funds (assuming conversion of
securities convertible into or exercisable or exchangeable for Voting
Securities) and the denominator of which is the total number of Voting
Securities outstanding; provided that notwithstanding the foregoing, if the
Funds beneficially own less than 5% of the outstanding Voting Securities, MSVP
III Fund shall no longer have the right to designate any nominee for election to
the Company's Board of Directors (the "Fund Nominees").
(b) The Company agrees to use its best efforts to increase the size of
the Board of Directors of the Company promptly after Closing by the number of
Directors as determined pursuant to Section 8.01(a) and shall appoint as
Directors of the Company (with a term expiring at the following annual meeting
of the Company's stockholders) such persons designated by MSVP III Fund.
SECTION 8.02. Reports. The Company agrees that the financial statements
of the Company shall be audited as of the end of each fiscal year by the
Company's independent certified public accountants. The Company's current
independent public accountants are Price Waterhouse LLP. In the event that Price
Waterhouse LLP ceases to be the Company's accountants, the Company agrees that
its independent public accountants thereafter shall be a nationally recognized
independent certified public accounting firm.
17
<PAGE>
SECTION 8.03. Pre-emptive Rights. (a) If the Company shall, other than
pursuant to any Excluded Issuance, issue any of its Voting Securities or
Convertible Securities, the Funds shall have the right to purchase for cash the
number or amount of such Voting Securities or Convertible Securities on the same
terms and at the same price as the issue price of such Voting Security or
Convertible Security (if such Voting Security or Convertible Security is to be
issued for consideration other than cash, at a cash price equal to the fair
market value of such non-cash consideration on the date the Company first agrees
to issue such Voting Securities or Convertible Securities) so that, after the
issuance of all such Voting Securities or Convertible Securities, the Funds
would, in the aggregate, hold the same proportional interest of such equity
securities (or, in the case of Convertible Securities, to be outstanding upon
conversion or exercise of all such Convertible Securities) as is held by it
prior to the issuance of any such additional equity securities or Convertible
Securities. An "Excluded Issuance" means any issuance of Voting Securities or
Convertible Securities pursuant to (i) any Common Stock Plan, (ii) upon
conversion of Convertible Securities of the Company outstanding on the date
hereof, (iii) upon an offering or sale to the public registered under the 1933
Act, (iv) pursuant to a stock dividend or stock split or other subdivision or
recombination of Voting Securities, (v) in connection with any Acquisition or
financing pursuant to an Acquisition, where the issuance is not registered at
the time of such issuance under the 1933 Act, (vi) in connection with any
equipment financing, collaborative arrangement or bank financing not intended to
provide equity financing, or (vii) any issuance pursuant to the Letter of Intent
between the Company and the Shady Grove Shareholders (as defined therein) dated
January 22, 1998, in connection with the acquisition of Shady Grove (as defined
therein). In the event the Company proposes to issue securities subject to the
provisions of this Section 8.03, the Company shall promptly deliver written
notice (a "Pre-emptive Rights Notice") of such proposed issuance to the Funds
setting forth the material terms and price. Each Fund's right to purchase
securities under this Section 8.03 with respect to any issuance of securities
shall terminate 15 days after the delivery of the Pre-emptive Rights Notice
unless the Funds elect to purchase securities pursuant to such Notice by sending
written notice to the Company prior thereto. The rights of the Funds under this
Section 8.03 shall terminate in their entirety upon the earlier of (i) the fifth
anniversary of the Closing Date and (ii) the Fund's ownership of Voting
Securities is less than 2% of the outstanding number of Voting Securities.
18
<PAGE>
(b) For the purposes of this Section 8.03, (i) the term "Acquisition"
shall mean any transaction, including, but not limited to, any purchase of
stock, assets or other business combination not intended to provide equity
financing, where the Company issues Voting Securities as consideration at a per
share value (based on the fair market value of the cash and non-cash
consideration obtained or acquired by the Company) not less than the lower of
(x) the average closing price per share of the Common Stock on the Nasdaq Stock
Market over the 10 trading days prior to the third business day before
consummation of such transaction and (y) the price as determined by a similar
market based formula set forth in the relevant transaction agreement; and (ii)
the term "fair market value" of any non-cash consideration on the date in
question shall mean the fair market value of such consideration as mutually
agreed by the Company and the Funds, or if such parties are unable to agree, as
determined by an investment banking firm mutually agreeable to both parties. In
the event that the parties are unable to agree on an investment banking firm,
then each party shall select a third investment banking firm to determine the
"fair market value" of any non-cash consideration. The fees and expenses of such
third investment banking firm shall be borne equally by the Company and the
Funds.
SECTION 8.04. Voting Arrangements. MSVP shall vote and cause to be
voted all Voting Securities owned by the Funds for nominees to the Board of
Directors of the Company who have been recommended by the Company's Board of
Directors.
ARTICLE 9
TERMINATION
SECTION 9.01. Grounds for Termination. This Agreement may be
terminated at any time:
(a) by mutual written agreement of the Company and each Fund; or
(b) by the Funds with respect to all of their respective obligations
hereunder if the Company shall fail to nominate for election or appoint to the
Company's Board of Directors the persons designated by MSVP III Fund pursuant to
Section 8.01.
The party desiring to terminate this Agreement shall give notice of such
termination to each other party.
SECTION 9.02. Effect of Termination. If this Agreement is terminated as
permitted by Section 9.01, termination shall be without liability of any party
(or any stockholder, director, officer, employee, agent, consultant or
representative of such party) to the other parties to this Agreement; provided
that if such termination shall result from the willful failure of any party to
fulfill a condition to the performance of the obligations of any other party or
to perform a covenant of this Agreement or from a willful breach by any party to
this Agreement, such party shall be fully liable for any and all damage, loss or
expense incurred or suffered by the other party or parties as a result of such
failure or breach. The provisions of Sections 10.02 and 10.04 survive any
termination hereof pursuant to Section 9.01. The provisions of Section 5.02 and
the Registration Rights Agreement (Exhibit A hereto) shall survive any
termination of this Agreement subsequent to the Closing.
19
<PAGE>
ARTICLE 10
MISCELLANEOUS
SECTION 10.01. Notices. All notices, requests and other communications
to any party hereunder shall be in writing (including facsimile transmission)
and shall be given,
if to the Funds, to:
Morgan Stanley Venture Partners
1221 Avenue of the Americas
33rd Floor
New York, NY 10020
Attention: M. Fazle Husain
Fax: (212) 762-8424
with a copy to:
Davis Polk & Wardwell
450 Lexington Avenue
New York, NY 10017
Attention: John A. Bick, Esq.
Fax: (212) 450-4800
if to the Company, to:
IntegraMed America, Inc.
One Manhattanville Road
Purchase, NY 10577
Attention: Gerardo Canet
Fax: (914) 253-8008
with a copy to:
Bachner, Tally, Polevoy & Misher LLP
380 Madison Avenue
New York, NY 10017
Attention: Alison S. Newman, Esq.
Fax: (212) 682-5729
20
<PAGE>
All such notices, requests and other communications shall be deemed received on
the date of receipt by the recipient thereof if received prior to 5 p.m. in the
place of receipt and such day is a business day in the place of receipt.
Otherwise, any such notice, request or communication shall be deemed not to have
been received until the next succeeding business day in the place of receipt.
SECTION 10.02. Survival. The representations and warranties of the
parties hereto contained in this Agreement or in any certificate or other
writing delivered pursuant hereto or in connection herewith shall survive the
Closing until eighteen months after the Closing Date.
SECTION 10.03. Amendments and Waivers. (a) Any provision of this
Agreement may be amended or waived prior to the Closing Date if, but only if,
such amendment or waiver is in writing and is signed, in the case of an
amendment, by each party to this Agreement, or in the case of a waiver, by the
party against whom the waiver is to be effective.
(b) No failure or delay by any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof nor shall any single or
partial exercise thereof preclude any other or further exercise thereof or the
exercise of any other right, power or privilege. The rights and remedies herein
provided shall be cumulative and not exclusive of any rights or remedies
provided by law.
SECTION 10.04. Expenses. All costs and expenses incurred by the parties
hereto in connection with the transactions contemplated by this Agreement shall
be the responsibility of such party. Notwithstanding anything to the contrary
contained in this Section 10.04, all reasonable fees and disbursements of the
Fund's legal counsel arising in connection with the transactions contemplated by
this Agreement (up to an amount equal to $25,000) shall be paid by the Company.
SECTION 10.05. Successors and Assigns. The provisions of this Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns; provided that except as expressly provided
herein no party may assign, delegate or otherwise transfer any of its rights or
obligations under this Agreement without the consent of each other party hereto.
SECTION 10.06. Governing Law. This Agreement shall be governed by and
construed in accordance with the law of the State of New York, without regard to
the conflicts of law rules of such state.
21
<PAGE>
SECTION 10.07. Counterparts; Third Party Beneficiaries. This Agreement
may be signed in any number of counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same
instrument. No provision of this Agreement is intended to confer upon any Person
other than the parties hereto any rights or remedies hereunder.
SECTION 10.08. Public Announcements. The Company and each Fund shall
agree on the form and content of any public announcements which shall be made
concerning this Agreement or the transactions contemplated hereby, and neither
the Company nor any Fund shall make any such public announcement without the
consent of the other, except with respect to any public announcement or other
public disclosure, to the extent either party determines, in good faith and with
the advice of counsel, such announcement or disclosure is required by law or the
rules or regulations of any exchange on which such party's securities are listed
or to avoid undue risk that the transactions contemplated hereby will be
enjoined or that such party, its officers, directors or representatives will be
liable for damages as a result thereof.
SECTION 10.09. Entire Agreement; Exhibits. This Agreement constitutes
the entire agreement among the parties with respect to the subject matter of
this Agreement and supersedes all prior agreements and understandings, both oral
and written, among the parties with respect to the subject matter of this
Agreement. No representation, inducement, promise, understanding, condition or
warranty not set forth herein has been made or relied upon by any party hereto.
All exhibits hereto constitute part of this Agreement and are expressly
incorporated herein.
SECTION 10.10. Headings. The headings and the table of contents
appearing in this Agreement are inserted only as a matter of convenience and for
reference and in no way define, limit or describe the scope and intent of this
Agreement or any of the provisions hereof.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their respective authorized officers as of the day and year
first above written.
INTEGRAMED AMERICA, INC.
By: /s/ Dwight Ryan
----------------
Name: Dwight Ryan
Title: Chief Financial Officer
MORGAN STANLEY VENTURE PARTNERS III, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
22
<PAGE>
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
-------------------
Name: M. Fazle Husain
Title: General Partner
By: /s/ M. Fazle Husain
-------------------
Name: M. Fazle Husain
Title:General Partner
MORGAN STANLEY VENTURE INVESTORS III, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
-------------------
Name: M. Fazle Husain
Title: General Partner
By: /s/ M. Fazle Husain
-------------------
Name: M. Fazle Husain
Title:General Partner
THE MORGAN STANLEY VENTURE PARTNERS
ENTREPRENEUR FUND, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
-------------------
Name: M. Fazle Husain
Title: General Partner
By: /s/ M. Fazle Husain
--------------------
Name: M. Fazle Husain
Title: General Partner
23
<PAGE>
Exhibit A
REGISTRATION RIGHTS
ARTICLE 1
DEFINITIONS
SECTION 1.01. Definitions. Terms defined in the Investment Agreement
(the "Agreement") dated as of January 23, 1998 among IntegraMed America, Inc., a
Delaware corporation (the "Company"), Morgan Stanley Venture Partners III, L.P.,
a Delaware limited partnership ("MSVP III Fund"), Morgan Stanley Venture
Investors III, L.P., a Delaware limited partnership ("Employee Fund") and The
Morgan Stanley Venture Partners Entrepreneur Fund, L.P., a Delaware limited
partnership ("Entrepreneur Fund") are used herein as therein defined. In
addition, the following terms, as used herein, have the following meanings:
"Demand Registration" means a Demand Registration as defined in Section
2.01.
"Form S-3 Registration" means a Form S-3 Registration as defined in
Section 2.03.
"Holder" means any person or persons owning or having the right to
acquire Registerable Securities.
"Piggyback Registration" means a Piggyback Registration as defined in
Section 2.02.
"Registerable Securities" means shares of Common Stock owned from time
to time by any Fund and its partners and Affiliates, and any other securities
issued by the Company in exchange for or upon conversion of any such securities.
"Underwriter" means a securities dealer who purchases any Registerable
Securities as principal and not as part of such dealer's market-making
activities.
1
<PAGE>
ARTICLE 2
REGISTRATION RIGHTS
SECTION 2.01. Demand Registration. (a) At any time after the first
anniversary of the Closing Date, Holders of at least fifty percent (50%) of the
Registerable Securities then outstanding may make up to two written requests for
registration under the 1933 Act of all or part of their Registerable Securities
(a "Demand Registration"); provided that the Company shall not be obligated to
effect a Demand Registration for Registerable Securities (i) more than once in
any 180 day period and (ii) for an aggregate public offering price of less than
$5 million and not less than an aggregate of 1,000,000 Registerable Securities
(as such number may be adjusted from time to time for any stock split, stock
dividend or other recapitalization or reclassification). Such request will
specify the number of shares of Registerable Securities proposed to be sold and
will also specify the intended method of disposition thereof. In connection with
any registration pursuant to this Section 2.01, the Company shall give written
notice of such registration to its stockholders who have rights similar to those
set forth in Section 2.02, and such notice shall offer, subject to the terms and
conditions hereof, each stockholder the opportunity to register shares as each
stockholder may request on the same terms and conditions as the Holders' shares.
A registration will not count as a Demand Registration until a registration
statement relating to such Demand Registration has become effective.
(b) If Holders so elect, the offering of such Registerable Securities
pursuant to such Demand Registration shall be in the form of an underwritten
offering. Holders shall have the right to appoint Morgan Stanley & Co.
Incorporated ("MS & Co."), as the book-running and managing Underwriter in
connection with such offering and any additional investment bankers and managers
to be used in connection with the offering. If Holders decline their right to
appoint MS & Co. as the book-running and managing Underwriter, the Company shall
select, subject to approval by Holders of a majority of the Registerable
Securities subject to such Demand Registration, the book-running and other
managing Underwriters in connection with such offering and any additional
investment bankers and managers to be used in connection with the offering. The
Company shall be obligated to cause senior management of the Company to
participate in any "road-show" in connection with the offering.
SECTION 2.02. Piggyback Registration. If the Company proposes to file a
registration statement under the 1933 Act with respect to an offering of Common
Stock (i) for the Company's own account (other than a registration statement on
Form S-4 or S-8 (or any substitute form that may be adopted by the Commission)
or relating solely to securities issued pursuant to any present or future
restricted stock, stock option, stock purchase or dividend reinvestment plan or
other similar type of plan of the Company which provides for the issuance of
equity securities or options or rights to purchase equity securities of the
Company), or (ii) for the account of any of its stockholders (not including
Holders), then the Company shall give written notice of such proposed filing to
each Holder as soon as practicable (but in no event less than 15 days before the
anticipated filing date), and such notice shall offer, subject to the terms and
conditions hereof, each Holder the opportunity to register such Registerable
Securities as each Holder may request on the same terms and conditions as the
Company's or such stockholders' shares (a "Piggyback Registration").
2
<PAGE>
SECTION 2.03. Form S-3 Registration. (a) At any time after the first
anniversary of the Closing Date, in case the Company shall receive from any
Holder or Holders who hold in excess of one percent (1%) of the Company's
outstanding Common Stock (including the number of shares of Common Stock into
which Convertible Securities may be converted) a written request or requests
that the Company effect a registration on Form S-3 and any related qualification
or compliance with respect to the Registerable Securities owned by such Holder
with an anticipated aggregate offering price, net of discounts and commissions,
of more than $2.5 million (a "Form S-3 Registration"), the Company will:
(i) promptly give written notice of the proposed registration, and any
related qualification or compliance, to all other stockholders having
registration rights, and such notice shall offer, subject to the terms
and conditions hereof, each stockholder the opportunity to register
shares as each stockholder may request on the same terms and conditions
as the Holders' shares; and
(ii) as soon as practicable, effect such registration and all such
qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion
of such Holder's or Holders' Registerable Securities as are specified
in such request, together with all or such portion of the Registerable
Securities of any other stockholders joining in such request as are
specified in a written request given within 15 days after receipt of
such written notice from the Company; provided that the Company shall
not be obligated to honor more than two requests for registration on
Form S-3 in any one year period. Registrations effected pursuant to
this Section 2.03(a)(ii) shall not be counted as demands for
registration or registrations effected pursuant to Section 2.01.
(b) If Holder or Holders so elect, the offering of such Registerable
Securities pursuant to such Form S-3 Registration shall be in the form of an
underwritten offering. Holders shall have the right to appoint MS & Co. as the
book-running and managing Underwriter in connection with such offering and any
additional investment bankers and managers to be used in connection with the
offering. If Holders decline their right to appoint MS & Co. as the book-running
and managing Underwriter, the Company shall select, subject to approval by
Holders of a majority of the Registerable Securities subject to such Form S-3
Registration, the book-running and other managing Underwriters in connection
with such offering and any additional investment bankers and managers to be used
in connection with the offering. The Company shall be obligated to cause senior
management of the Company to participate in any "road-show" in connection with
the offering.
3
<PAGE>
SECTION 2.04. Reduction of Offering. Notwithstanding anything contained
herein, if the managing Underwriter or Underwriters of an offering described in
Section 2.01, 2.02 or 2.03 shall advise the Company that the size of the
offering that Holder, the Company and any other Persons intend to make is such
that the success of the offering would be materially and adversely affected,
then the amount of Registerable Securities to be offered for the account of
Holder shall be reduced to the extent necessary to reduce the total amount of
securities to be included in such offering to the amount recommended by such
managing Underwriter or Underwriters; provided that (x) in the case of a Demand
Registration by Holders or Form S-3 Registration pursuant to Section 2.03
hereof, the amount of Registerable Securities to be offered for the account of
the Holder shall be reduced only after (1) the amount of securities to be
offered for the account of such other Persons has been reduced to zero, and then
(2) the amount of securities to be offered for the account of the Company has
been reduced to zero, and (y) in the case of a Piggyback Registration (1) that
is initiated by the Company for its own account and where securities are being
offered for the account of Persons other than the Company, then the proportion
by which the amount of such Registerable Securities intended to be offered for
the account of Holder is reduced shall not exceed the proportion by which the
amount of such securities intended to be offered for the account of such other
Persons is reduced, such reduction shall be effected before any reduction of the
number of securities offered for the account of the Company, or (2) that is
initiated for the account of Persons other than the Company, the amount of
Registerable Securities to be offered for the account of the Company, if any,
shall be reduced only after (A) the amount of securities to be offered for the
account of Holders has been reduced to zero, and then (B) the amount of
securities to be offered for the account of such other Persons has been reduced
to zero.
SECTION 2.05. General Limitations. Any Demand Registration requested
under Section 2.01 shall, if the Company is eligible to use Form S-3 (or any
successor form) under the 1933 Act, be effected on a Form S-3 Registration.
Notwithstanding anything to the contrary in this Article 2, the Company shall
not be obligated pursuant to Section 2.01 and Section 2.03 hereof to effect more
than an aggregate of two registrations in any one year period.
4
<PAGE>
ARTICLE 3
REGISTRATION PROCEDURES
SECTION 3.01. Filings; Information. Whenever a Holder requests a Demand
Registration or Form S-3 Registration, the Company will use its best efforts to
effect the registration of such Registerable Securities as quickly as
practicable, and in connection with any such request:
(a) The Company will as expeditiously as possible prepare and file with
the Commission a registration statement on any form for which the Company then
qualifies and which counsel for the Company shall deem appropriate and available
for the sale of the Registerable Securities to be registered thereunder in
accordance with the intended method of distribution thereof, and use reasonable
best efforts to cause such filed registration statement to become and remain
effective for a period of not less than 120 days; provided that (i) if the
Company shall furnish to Holder a certificate signed by its Chairman, Chief
Executive Officer or Chief Financial Officer stating that in his or her good
faith judgment it would be detrimental or otherwise disadvantageous to the
Company or its stockholders for such a registration statement to be filed, or,
in the case of an effective registration statement, for sales to be effected
thereunder, the Company shall have a period of not more than 120 days within
which to file such registration statement measured from the date of receipt of
the request in accordance with Section 2.01 or, in the case of an effective
registration statement, the Company shall be entitled to require Holder to
refrain from selling Registerable Securities under such registration statement
for a period of up to 120 days and (ii) the Company shall not be obligated to
file any registration statement pursuant to Sections 2.01 and Section 2.03
hereof if the Company has filed within the previous 120 days a registration
statement under the 1933 Act (other than on Form S-8); provided further that, in
the case of a registration statement to be filed, the Company shall be entitled
to only one 120 day delay in any 360 day period, and, in the case of an
effective registration statement, the Company shall be entitled to require
Holder to refrain from selling Registerable Securities under such Registration
Statement for an aggregate of 120 days in any 360 day period. If the Company
furnishes a notice under this paragraph at a time when a registration statement
filed pursuant to this Agreement is effective, the Company shall extend the
period during which such registration statement shall be maintained effective as
provided in this Section 3.01(a) hereof by the number of days during the period
from and including the date of the giving of notice under this paragraph to the
date when sales under the registration statement may recommence.
5
<PAGE>
(b) The Company will, if requested, prior to filing such registration
statement or any amendment or supplement thereto, furnish to a representative
designated by Holders of a majority of the Registerable Securities covered by
such registration statement and each managing Underwriter, if any, copies
thereof, and thereafter furnish to each Holder and each such Underwriter, if
any, such number of copies of such registration statement, each amendment and
supplement thereto (in each case including all exhibits thereto and documents
incorporated by reference therein) and the prospectus included in such
registration statement (including each preliminary prospectus) as such Holder or
such Underwriter may reasonably request in order to facilitate the sale of the
Registerable Securities.
(c) After the filing of the registration statement, the Company will
promptly notify each Holder of any stop order issued or, to the knowledge of the
Company, threatened to be issued by the Commission and take all necessary
actions required to prevent the entry of such stop order or to remove it if
entered.
(d) The Company will use its reasonable best efforts to qualify the
Registerable Securities for offer and sale under such other securities or blue
sky laws of such jurisdictions in the United States as Holders reasonably (in
light of Holders' intended plan of distribution) request; provided that the
Company will not be required to (i) qualify generally to do business in any
jurisdiction where it would not otherwise be required to qualify but for this
paragraph (d), (ii) subject itself to taxation in any such jurisdiction or (iii)
generally consent to service of process in any such jurisdiction.
(e) The Company shall, as promptly as practicable, notify each Holder,
at any time when a prospectus relating to the sale of the Registerable
Securities is required by law to be delivered in connection with sales by an
Underwriter or dealer, of the occurrence of an event requiring the preparation
of a supplement or amendment to such registration statement or prospectus so
that, as thereafter delivered to the purchasers of such Registerable Securities,
such registration statement or prospectus will not contain an untrue statement
of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and as promptly as
practicable make available to Holders and to the Underwriters any such
supplement or amendment. Each Holder agrees that, upon receipt of any notice
from the Company of the happening of any event of the kind described in the
preceding sentence, Holder will forthwith discontinue the offer and sale of
Registerable Securities pursuant to the registration statement covering such
Registerable Securities until receipt of the copies of such supplemented or
amended prospectus and, if so directed by the Company, Holder will deliver to
the Company all copies, other than permanent file copies then in Holder's
possession, of the most recent prospectus covering such Registerable Securities
at the time of receipt of such notice. In the event the Company shall give such
notice, the Company shall extend the period during which such registration
statement shall be maintained effective as provided in Section 3.01(a) hereof by
the number of days during the period from and including the date of the giving
of such notice to the date when the Company shall make available to Holders such
supplemented or amended prospectus.
6
<PAGE>
(f) The Company will enter into customary agreements (including an
underwriting agreement in customary form and satisfactory in form and substance
to the Company in its reasonable judgment) and take such other actions as are
reasonably required in order to expedite or facilitate the sale of such
Registerable Securities.
(g) The Company will furnish to each Holder and to each managing
Underwriter, if any, a signed counterpart, addressed to each Holder and each
Underwriter, of (i) an opinion or opinions of counsel to the Company and (ii) a
comfort letter or comfort letters from the Company's independent public
accountants, each in customary form and covering such matters of the type
customarily covered by opinions or comfort letters delivered to such parties.
(h) The Company will make generally available to its securityholders,
as soon as reasonably practicable, an earnings statement covering a period of 12
months, beginning within three months after the effective date of the
registration statement, which earnings statement shall satisfy the provisions of
Section 11(a) of the 1933 Act.
(i) The Company will use its best efforts to cause all such
Registerable Securities covered by such Registration Statement to be listed on
each securities exchange on which similar securities issued by the Company are
then listed.
The Company may require each Holder promptly to furnish in writing to
the Company such information regarding such Holder, the plan of distribution of
the Registerable Securities and other information as the Company may from time
to time reasonably request or as may be legally required in connection with such
registration.
SECTION 3.02. Registration Expenses. In connection with any Demand
Registration, Piggyback Registration or Form S-3 Registration, the Company shall
pay the following expenses incurred in connection with such registration (the
"Registration Expenses"): (i) all filing fees with the Commission and the
National Association of Securities Dealers, (ii) fees and expenses of compliance
with securities or blue sky laws (including reasonable fees and disbursements of
counsel in connection with blue sky qualifications of the Registerable
Securities), (iii) printing expenses, (iv) the fees and expenses incurred in
connection with the listing of the Registerable Securities, (v) fees and
expenses of counsel and independent certified public accountants for the Company
(including the expenses of any comfort letters pursuant to Section 3.01(g)
hereof) and (vi) the reasonable fees and expenses of any additional experts
retained by the Company in connection with such registration. Each Holder shall
pay any underwriting fees, discounts or commissions and the fees and expenses of
counsel to the Holders of Registerable Securities attributable to the sale of
Registerable Securities of such Holder. The Company shall pay internal Company
expenses (including, without limitation, all salaries and expenses of its
officers and employees performing legal or accounting duties).
7
<PAGE>
ARTICLE 4
INDEMNIFICATION AND CONTRIBUTION
SECTION 4.01. Indemnification by the Company. The Company agrees to
indemnify and hold harmless each Holder, its officers and directors, and each
Person, if any, who controls such Holder within the meaning of either Section 15
of the 1933 Act or Section 20 of the 1934 Act from and against any and all
losses, claims, damages and liabilities caused by any untrue statement or
alleged untrue statement of a material fact contained in any registration
statement or prospectus relating to the Registerable Securities (as amended or
supplemented if the Company shall have furnished any amendments or supplements
thereto) or any preliminary prospectus (including documents incorporated by
reference therein), or caused by any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, except insofar as such losses, claims,
damages or liabilities are caused by any such untrue statement or omission or
alleged untrue statement or omission based upon information furnished in writing
to the Company by or on behalf of such Holder expressly for use therein;
provided that the foregoing indemnity agreement with respect to any preliminary
prospectus shall not inure to the benefit of such Holder if a copy of the then
current prospectus was not provided to purchaser at or prior to the time of such
purchase and such current prospectus would have cured the defect giving rise to
such loss, claim, damage or liability or for any sales occurring during the
period in which the Company is not required to keep the registration statement
effective as provided in Section 3.01(a) or after the Company has informed such
Holder under Section 3.01(e) and prior to the delivery by the Company of any
supplement or amendment to such prospectus. The Company also agrees to indemnify
any Underwriters of the Registerable Securities, their officers and directors
and each person who controls such underwriters on substantially the same basis
as that of the indemnification of such Holder provided in this Section 4.01.
8
<PAGE>
SECTION 4.02. Indemnification by Holder. Each Holder agrees to
indemnify and hold harmless the Company, its officers and directors, and each
Person, if any, who controls the Company within the meaning of either Section 15
of the 1933 Act or Section 20 of the 1934 Act to the same extent as the
foregoing indemnity from the Company to such Holder, but only with reference to
information furnished in writing by or on behalf of such Holder expressly for
use in any registration statement or prospectus relating to the Registerable
Securities, or any amendment or supplement thereto, or any preliminary
prospectus. Each Holder also agrees to indemnify and hold harmless Underwriters
of the Registerable Securities, their officers and directors and each person who
controls such Underwriters on substantially the same basis as that of the
indemnification of the Company provided in this Section 4.02.
SECTION 4.03. Conduct of Indemnification Proceedings. In case any
proceeding (including any governmental investigation) shall be instituted
involving any Person in respect of which indemnity may be sought pursuant to
Section 4.01 or 4.02, such Person (the "Indemnified Party") shall promptly
notify the Person against whom such indemnity may be sought (the "Indemnifying
Party") in writing and the Indemnifying Party, upon the request of the
Indemnified Party, shall retain counsel reasonably satisfactory to such
Indemnified Party to represent such Indemnified Party and any others the
Indemnifying Party may designate in such proceeding and shall pay the fees and
disbursements of such counsel related to such proceeding. In any such
proceeding, any Indemnified Party shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of
such Indemnified Party unless (i) the Indemnifying Party and the Indemnified
Party shall have mutually agreed to the retention of such counsel or (ii) the
named parties to any such proceeding (including any impleaded parties) include
both the Indemnified Party and the Indemnifying Party and representation of both
parties by the same counsel would, in the opinion of counsel reasonably
acceptable to the Indemnifying Party, be inappropriate due to actual or
potential differing interests between them. It is understood that the
Indemnifying Party shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the fees and expenses of
more than one separate firm of attorneys (in addition to any local counsel) at
any time for all such Indemnified Parties, and that all such fees and expenses
shall be reimbursed as they are incurred. In the case of any such separate firm
for the Indemnified Parties, such firm shall be designated in writing by the
Indemnified Parties. The Indemnifying Party shall not be liable for any
settlement of any proceeding effected without its written consent, but if
settled with such consent, or if there be a final judgment for the plaintiff,
the Indemnifying Party shall indemnify and hold harmless such Indemnified
Parties from and against any loss or liability (to the extent stated above) by
reason of such settlement or judgment.
9
<PAGE>
SECTION 4.04. Contribution. If the indemnification provided for in this
Article 4 is unavailable to the Indemnified Parties in respect of any losses,
claims, damages or liabilities referred to herein, then each Indemnifying Party,
in lieu of indemnifying such Indemnified Party, shall contribute to the amount
paid or payable by such Indemnified Party as a result of such losses, claims,
damages or liabilities (i) in such proportion as is appropriate to reflect the
relative benefits received by the Company and each Holder from the offering of
the securities, or (ii) if the allocation provided by clause (i) above is not
permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) but also the relative fault
of the Company and each Holder in connection with the statements or omissions
which resulted in such losses, claims, damages or liabilities, as well as any
other relevant equitable considerations. The relative benefits received by the
Company and each Holder shall be deemed to be in the same proportion as the
total proceeds from the offering (net of underwriting discounts and commissions
but before deducting expenses) received by the Company and each Holder, in each
case as set forth in the table on the cover page of the prospectus, bear to the
aggregate public offering price of the securities. The relative fault of the
Company and each Holder shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information
supplied by such party and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The Company and each Holder agree that it would not be just and
equitable if contribution pursuant to this Section 4.04 were determined by pro
rata allocation or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. The amount paid or payable by an Indemnified Party as a result of the
losses, claims, damages or liabilities referred to in the immediately preceding
paragraph shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such Indemnified Party
in connection with investigating or defending any such action or claim. No
person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the 1933 Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.
ARTICLE 5
MISCELLANEOUS
SECTION 5.01. Participations in Underwritten Registrations. No Person
may participate in any underwritten registered offering contemplated hereunder
unless such Person (a) agrees to sell its securities on the basis provided in
any underwriting arrangements and (b) completes and executes all questionnaires,
powers of attorney, indemnities, underwriting agreements and other documents
reasonably required under the terms of such underwriting arrangements and these
Registration Rights.
10
<PAGE>
SECTION 5.02. Rule 144. The Company covenants that it will use best
efforts to file any reports required to be filed by it under the 1933 Act and
the 1934 Act and that it will take such further action as Holders may reasonably
request, all to the extent required from time to time to enable Holders to sell
Registerable Securities without registration under the 1933 Act within the
limitation of the exemptions provided by Rule 144 under the 1933 Act, as such
Rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission. Upon the request of a Holder, the Company
will deliver to such Holder a written statement as to whether it has complied
with such requirements.
SECTION 5.03. Holdback Agreements. (a) Each Holder agrees not to offer,
sell, contract to sell or otherwise dispose of any Registerable Securities, or
any securities convertible into or exchangeable or exercisable for such
securities, from the date of filing of a registration statement relating to the
sale of Registerable Securities through the 90 day period beginning on the date
of the first sale of Registerable Securities pursuant to the registration
statement other than the Registerable Securities to be sold pursuant to such
registration statement.
(b) The Company agrees not to offer, sell, contract to sell or
otherwise dispose of any securities similar to the Registerable Securities to be
sold pursuant hereto, or any securities convertible into or exchangeable or
exercisable for such securities, during the 14 days prior to, and during the 90
day period beginning on, the effective date of any registration statement
registering the Registerable Securities other than any shares of Common Stock
sold upon the exercise of an option or warrant or the conversion of a security
outstanding at such date or pursuant to any Common Stock Plan or issued by the
Company as consideration for an acquisition or other transaction not intended to
provide equity financing.
SECTION 5.04. Termination of Company Obligations. All registration
rights provided hereunder shall terminate with respect to any Holder at such
time as such Holder holds less than 5% of the outstanding common stock and is
able to sell all of its Registerable Securities under Rule 144 without
registration under the 1933 Act during any single three month period.
11
<PAGE>
Exhibit B
INTEGRAMED AMERICA, INC.
WARRANT FOR THE PURCHASE OF SHARES OF
COMMON STOCK OF INTEGRAMED AMERICA, INC.
No. ____ Warrant to Purchase
_________ Shares
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD
EXCEPT IN COMPLIANCE THEREWITH.
FOR VALUE RECEIVED, INTEGRAMED AMERICA, INC., a Delaware corporation
(the "Company"), hereby certifies that [Name of Morgan Stanley Venture Fund],
its successor or permitted assigns (the "Holder"), is entitled, subject to the
provisions of this Warrant, to purchase from the Company, at the times specified
herein, a number of fully paid and non-assessable shares of Common Stock of the
Company, par value $.01 per share (the "Common Stock"), equal to the Warrant
Shares (as hereinafter defined) at a purchase price per share equal to the
Exercise Price (as hereinafter defined). The number of Warrant Shares to be
received upon the exercise of this Warrant is subject to adjustment from time to
time as hereinafter set forth.
1. Definitions. (a) The following terms, as used herein, have the
following meanings:
"Affiliate" shall have the meaning given to such term in Rule 12b-2
promulgated under the Securities and Exchange Act of 1934, as amended.
"Business Day" means any day except a Saturday, Sunday or other day on
which commercial banks in the City of New York are authorized by law to close.
"Common Stock" means the Common Stock, par value $.01 per share, of the
Company.
"Duly Endorsed" means duly endorsed in blank by the Person or Persons
in whose name a stock certificate is registered or accompanied by a duly
executed stock assignment separate from the certificate with the signature(s)
thereon guaranteed by a commercial bank or trust company or a member of a
national securities exchange or of the National Association of Securities
Dealers, Inc.
"Exercise Price" means $.01 per Warrant Share.
"Expiration Date" means the fourth anniversary of the date hereof at
5:00 p.m. New York City time.
"Investment Agreement" means the Investment Agreement dated as of
January 23, 1998 among the Company and the Shareholders listed on the signature
pages thereto, providing for the purchase and issuance of the Shares and this
Warrant.
"Person" means an individual, partnership, corporation, trust, joint
stock company, association, joint venture, or any other entity or organization,
including a government or political subdivision or an agency or instrumentality
thereof.
"Principal Holder" means the original Holder of this Warrant on the
date of issue, or if such original Holder so elects, any transferee of all or
any portion of this Warrant whom such original Holder shall have designated by
written notice to the Company as the successor Principal Holder. Any successor
Principal Holder designated pursuant to the immediately preceding sentence shall
also have the right upon any subsequent transfer to designate a successor
Principal Holder in the manner described above.
1
<PAGE>
"Shareholders" means the Shareholders listed on the signature pages to
the Investment Agreement.
"Shares" means the shares of Common Stock purchased by the
Shareholders pursuant to the Investment Agreement.
"Warrant Shares" means the ________ shares of Common Stock deliverable
upon exercise of this Warrant, as adjusted from time to time.
(b) Capitalized terms used but not defined herein shall have the
meanings given them in the Investment Agreement.
2. Exercise of Warrant.
(a) The Holder is entitled to exercise this Warrant in whole or in
part at any time, or from time to time, until the Expiration Date or,
if such day is not a Business Day, then on the next succeeding day that
shall be a Business Day. To exercise this Warrant, the Holder shall
execute and deliver to the Company a Warrant Exercise Notice
substantially in the form annexed hereto. No earlier than ten days
after delivery of the Warrant Exercise Notice, the Holder shall deliver
to the Company this Warrant Certificate, including the Warrant Exercise
Subscription Form forming a part hereof duly executed by the Holder,
together with payment of the applicable Exercise Price. Upon such
delivery and payment, the Holder shall be deemed to be the holder of
record of the Warrant Shares subject to such exercise, notwithstanding
that the stock transfer books of the Company shall then be closed or
that certificates representing such Warrant Shares shall not then be
actually delivered to the Holder.
(b) The Exercise Price may be paid in cash or by certified or
official bank check or bank cashier's check payable to the order of the
Company or by any combination of such cash or check. The Company shall
pay any and all documentary, stamp or similar issue or transfer taxes
payable in respect of the issue or delivery of the Warrant Shares.
(c) If the Holder exercises this Warrant in part, this Warrant
Certificate shall be surrendered by the Holder to the Company and a new
Warrant Certificate of the same tenor and for the unexercised number of
Warrant Shares shall be executed by the Company. The Company shall
register the new Warrant Certificate in the name of the Holder or in
such name or names of its transferee pursuant to paragraph 6 hereof as
may be directed in writing by the Holder and deliver the new Warrant
Certificate to the Person or Persons entitled to receive the same.
(d) Upon surrender of this Warrant Certificate in conformity with
the foregoing provisions, the Company shall transfer to the Holder of
this Warrant Certificate appropriate evidence of ownership of the
shares of Common Stock or other securities or property (including any
money) to which the Holder is entitled, registered or otherwise placed
in, or payable to the order of, the name or names of the Holder or such
transferee as may be directed in writing by the Holder, and shall
deliver such evidence of ownership and any other securities or property
(including any money) to the Person or Persons entitled to receive the
same, together with an amount in cash in lieu of any fraction of a
share as provided in paragraph 5 below.
3. Restrictive Legend. Certificates representing shares of Common Stock
issued pursuant to this Warrant shall bear a legend substantially in the form of
the legend set forth on the first page of this Warrant Certificate to the extent
that and for so long as such legend is required pursuant to the Investment
Agreement.
4. Reservation of Shares. The Company hereby agrees that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of its authorized but unissued shares of Common Stock or other
securities of the Company from time to time issuable upon exercise of this
Warrant as will be sufficient to permit the exercise in full of this Warrant.
All such shares shall be duly authorized and, when issued upon such exercise,
shall be validly issued, fully paid and non-assessable, free and clear of all
liens, security interests, charges and other encumbrances or restrictions on
sale and free and clear of all preemptive rights, except to the extent set forth
in the Investment Agreement.
2
<PAGE>
5. Fractional Shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant and in lieu
of delivery of any such fractional share upon any exercise hereof, the Company
shall pay to the Holder an amount in cash equal to such fraction multiplied by
the Current Market Price Per Common Share at the date of such exercise. For the
purpose of any computation under this paragraph 5, on any determination date the
Current Market Price Per Common Share shall be deemed to be the average
(weighted by daily trading volume) of the Daily Prices (as defined below) per
share of the applicable class of Common Stock for the 20 consecutive trading
days immediately prior to such date. "Daily Price" means (A) the last reported
sale price on such day if the Common Stock is listed on a national securities
exchange or admitted to unlisted trading privileges on such exchange or listed
for trading on the Nasdaq National Market; or (B) if the shares of such class of
Common Stock then are not so listed or admitted to unlisted trading privileges
but is traded on the Nasdaq Small Cap Market, the average of the closing bid and
asked prices for such day on such market and if the Common Stock is not so
traded, the current market value shall be the mean of the last reported bid and
asked prices reported by the National Quotation Bureau, Inc., on the last
business day prior to the determination date. If on any determination date the
shares of such class of Common Stock are not so listed or admitted to unlisted
trading privileges and bid and asked prices are not so reported, the Current
Market Price Per Common Share shall be the fair market value of such shares on
such determination date as determined by the Board of Directors. If the
Principal Holder shall object to any determination by the Board of Directors of
the Current Market Price Per Common Share, the Current Market Price Per Common
Share shall be the fair market value per share of the applicable class of Common
Stock as determined by an independent appraiser retained by the Company at its
expense and reasonably acceptable to the Principal Holder. For purposes of any
computation under this paragraph 5, the number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for
the account of the Company.
6. Exchange, Transfer or Assignment of Warrant.
(a) This Warrant Certificate and all rights hereunder are not
transferable by the registered holder hereof except to any Person who,
prior to such transfer, agrees in writing, in form and substance
reasonably satisfactory to the Company, to be bound by the terms of the
Investment Agreement in accordance with the provisions thereof. Each
taker and holder of this Warrant Certificate by taking or holding the
same, consents and agrees that the registered holder hereof may be
treated by the Company and all other persons dealing with this Warrant
Certificate as the absolute owner hereof for any purpose and as the
person entitled to exercise the rights represented hereby.
(b) The Holder of this Warrant shall be entitled, without
obtaining the consent of the Company to assign and transfer this
Warrant, at any time in whole or from time to time in part, to any
Person or Persons. Subject to the preceding sentence, upon surrender of
this Warrant to the Company, together with the attached Warrant
Assignment Form duly executed, the Company shall, without charge,
execute and deliver a new Warrant in the name of the assignee or
assignees named in such instrument of assignment and, if the Holder's
entire interest is not being assigned, in the name of the Holder and
this Warrant shall promptly be canceled.
7. Loss or Destruction of Warrant. Upon receipt by the Company of
evidence satisfactory to it (in the exercise of its reasonable discretion) of
the loss, theft, destruction or mutilation of this Warrant Certificate, and (in
the case of loss, theft or destruction) of reasonably satisfactory
indemnification, and upon surrender and cancellation of this Warrant
Certificate, if mutilated, the Company shall execute and deliver a new Warrant
Certificate of like tenor and date.
3
<PAGE>
8. Anti-dilution Provisions. In case the Company shall at any time
after the date hereof (i) declare a dividend or make a distribution on Common
Stock payable in Common Stock, (ii) subdivide or split the outstanding Common
Stock, (iii) combine or reclassify the outstanding Common Stock into a smaller
number of shares, or (iv) issue any shares of its capital stock in a
reclassification of Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), the number of Warrant Shares in effect at the time of the record
date for such dividend or distribution or of the effective date of such
subdivision, split, combination or reclassification shall be proportionately
adjusted so that the exercise of this Warrant after such time shall entitle the
holder to receive the aggregate number of shares of Common Stock or other
securities of the Company (or shares of any security into which such shares of
Common Stock have been reclassified pursuant to clause 8(a)(iii) or 8(a)(iv)
above) which, if this Warrant had been exercised immediately prior to such time,
such holder would have owned upon such exercise and been entitled to receive by
virtue of such dividend, distribution, subdivision, split, combination or
reclassification. An adjustment made pursuant to this Section 8(a) shall become
effective immediately after such record date in the case of a dividend or a
distribution and immediately after the effective date in the case of a
subdivision, split, combination or reclassification. Such adjustment shall be
made successively whenever any event listed above shall occur.
9. Consolidation, Merger, or Sale of Assets. In case of any
consolidation of the Company with, or merger of the Company into, any other
Person, any merger of another Person into the Company (other than a merger which
does not result in any reclassification, conversion, exchange or cancellation of
outstanding shares of Common Stock) or any sale or transfer of all or
substantially all of the assets of the Company or of the Person formed by such
consolidation or resulting from such merger or which acquires such assets, as
the case may be, the Holder shall have the right thereafter to exercise this
Warrant for the kind and amount of securities, cash and other property
receivable upon such consolidation, merger, sale or transfer by a holder of the
number of shares of Common Stock for which this Warrant may have been exercised
immediately prior to such consolidation, merger, sale or transfer, assuming (i)
such holder of Common Stock is not a Person with which the Company consolidated
or into which the Company merged or which merged into the Company or to which
such sale or transfer was made, as the case may be ("constituent Person"), or an
Affiliate of a constituent Person and (ii) in the case of a consolidation,
merger, sale or transfer which includes an election as to the consideration to
be received by the holders, such holder of Common Stock failed to exercise its
rights of election, as to the kind or amount of securities, cash and other
property receivable upon such consolidation, merger, sale or transfer (provided
that if the kind or amount of securities, cash and other property receivable
upon such consolidation, merger, sale or transfer is not the same for each share
of Common Stock held immediately prior to such consolidation, merger, sale or
transfer by other than a constituent Person or an Affiliate thereof and in
respect of which such rights of election shall not have been exercised
("non-electing share"), then for the purpose of this paragraph 9, the kind and
amount of securities, cash and other property receivable upon such
consolidation, merger, sale or transfer by each non-electing share shall be
deemed to be the kind and amount so receivable per share by a plurality of the
non-electing shares). Adjustments for events subsequent to the effective date of
such a consolidation, merger and sale of assets shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Warrant. In any such
event, effective provisions shall be made in the certificate or articles of
incorporation of the resulting or surviving corporation, in any contract of
sale, conveyance, lease or transfer, or otherwise so that the provisions set
forth herein for the protection of the rights of the Holder shall thereafter
continue to be applicable; and any such resulting or surviving corporation shall
expressly assume the obligation to deliver, upon exercise, such shares of stock,
other securities, cash and property. The provisions of this paragraph 9 shall
similarly apply to successive consolidations, mergers, sales, leases or
transfers.
4
<PAGE>
10. Notices. Any notice, demand or delivery authorized by this Warrant
Certificate shall be in writing and shall be given to the Holder, the Company or
the Shareholder Representative, as the case may be, at its address (or
telecopier number) set forth below, or such other address (or telecopier number)
as shall have been furnished to the party giving or making such notice, demand
or delivery:
If to the Company:
IntegraMed America, Inc.
One Manhattanville Road
Purchase, New York 10577
Telecopy: (914) 253-8008
Attention: Gerardo Canet
If to the Holder:
Morgan Stanley Venture Partners
1221 Avenue of the Americas
New York, New York 10020
Telecopy: (212) 762-8424
Attention: M. Fazle Husain
5
<PAGE>
Each such notice, demand or delivery shall be effective (i) if given by
telecopy, when such telecopy is transmitted to the telecopy number specified
herein and the intended recipient confirms the receipt of such telecopy or (ii)
if given by any other means, when received at the address specified herein.
11. Rights of the Holder. Prior to the exercise of any Warrant, the
Holder shall not, by virtue hereof, be entitled to any rights of a shareholder
of the Company, including, without limitation, the right to vote, to receive
dividends or other distributions, to exercise any preemptive right or to receive
any notice of meetings of shareholders or any notice of any proceedings of the
Company except as may be specifically provided for herein.
12. GOVERNING LAW. THIS WARRANT CERTIFICATE AND ALL RIGHTS ARISING
HEREUNDER SHALL BE CONSTRUED AND DETERMINED IN ACCORDANCE WITH THE INTERNAL LAWS
OF THE STATE OF NEW YORK, AND THE PERFORMANCE THEREOF SHALL BE GOVERNED AND
ENFORCED IN ACCORDANCE WITH SUCH LAWS.
13. Amendments; Waivers. Any provision of this Warrant Certificate may
be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by the Holder and the Company, or in the
case of a waiver, by the party against whom the waiver is to be effective. No
failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by law.
IN WITNESS WHEREOF, the Company has duly caused this Warrant
Certificate to be signed by its duly authorized officer and to be dated as of
January 23, 1998.
INTEGRAMED AMERICA, INC.
By:
Name:
Title:
Acknowledged and Agreed:
[Name of Morgan Stanley Venture Fund]
By:
Title:
6
<PAGE>
WARRANT EXERCISE NOTICE
(To be delivered prior to exercise of the Warrant
by execution of the Warrant Exercise Subscription Form)
To: IntegraMed America, Inc.
The undersigned hereby notifies you of its intention to exercise the
Warrant to purchase shares of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. The undersigned intends to exercise the Warrant to
purchase ___________ shares (the "Shares") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant). The undersigned intends to pay the
aggregate Exercise Price for the Shares in cash, certified or official bank or
bank cashier's check (or a combination of cash and check) as indicated below.
Date:_____________________________
_____________________________________________________
(Signature of Owner)
_____________________________________________________
(Street Address)
_____________________________________________________
(City) (State) (Zip Code)
Payment: $__________________ cash
$__________________ check
<PAGE>
WARRANT EXERCISE SUBSCRIPTION FORM
(To be executed only upon exercise of the Warrant
after delivery of Warrant Exercise Notice)
To: IntegraMed America, Inc.
The undersigned irrevocably exercises the Warrant for the purchase of
___________ shares (the "Shares") of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. (the "Company") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant) and herewith makes payment of
$___________ (such payment being made in cash or by certified or official bank
or bank cashier's check payable to the order of the Company or by any permitted
combination of such cash or check), all on the terms and conditions specified in
the within Warrant Certificate, surrenders this Warrant Certificate and all
right, title and interest therein to the Company and directs that the Shares
deliverable upon the exercise of this Warrant be registered or placed in the
name and at the address specified below and delivered thereto.
Date: _____________________________
----------------------------------------------------
(Signature of Owner)
-----------------------------------------------------
(Street Address)
-----------------------------------------------------
(City) (State) (Zip Code)
<PAGE>
Securities and/or check to be issued to:_______________________________________
Please insert social security or identifying number:___________________________
Name: _________________________________________________________________________
Street Address:________________________________________________________________
City, State and Zip Code:______________________________________________________
Any unexercised portion of the Warrant evidenced by the within Warrant
Certificate to be issued to:
Please insert social security or identifying number: __________________________
Name:__________________________________________________________________________
Street Address:________________________________________________________________
City, State and Zip Code:______________________________________________________
<PAGE>
WARRANT ASSIGNMENT FORM
Dated ___________ ___, _____
FOR VALUE RECEIVED, _______________________ hereby sells,
assigns and transfers unto_____________________________(the "Assignee"),
(please type or print in block letters)
________________________________________________________________________________
(insert address)
its right to purchase up to shares of Common Stock represented by this Warrant
and does hereby irrevocably constitute and appoint _______________________
Attorney, to transfer the same on the books of the Company, with full power of
substitution in the premises.
Signature:
INTEGRAMED AMERICA, INC.
WARRANT FOR THE PURCHASE OF SHARES OF
COMMON STOCK OF INTEGRAMED AMERICA, INC.
No. 1 Warrant to Purchase
Void after January 23, 2002 210,655 Shares
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD
EXCEPT IN COMPLIANCE THEREWITH.
FOR VALUE RECEIVED, INTEGRAMED AMERICA, INC., a Delaware corporation
(the "Company"), hereby certifies that Morgan Stanley Venture Partners III,
L.P., its successor or permitted assigns (the "Holder"), is entitled, subject to
the provisions of this Warrant, to purchase from the Company, at the times
specified herein, a number of fully paid and non-assessable shares of Common
Stock of the Company, par value $.01 per share (the "Common Stock"), equal to
the Warrant Shares (as hereinafter defined) at a purchase price per share equal
to the Exercise Price (as hereinafter defined). The number of Warrant Shares to
be received upon the exercise of this Warrant is subject to adjustment from time
to time as hereinafter set forth.
1. Definitions. (a) The following terms, as used herein, have the
following meanings:
"Affiliate" shall have the meaning given to such term in Rule 12b-2
promulgated under the Securities and Exchange Act of 1934, as amended.
"Business Day" means any day except a Saturday, Sunday or other day on
which commercial banks in the City of New York are authorized by law to close.
"Common Stock" means the Common Stock, par value $.01 per share, of
the Company.
"Duly Endorsed" means duly endorsed in blank by the Person or Persons
in whose name a stock certificate is registered or accompanied by a duly
executed stock assignment separate from the certificate with the signature(s)
thereon guaranteed by a commercial bank or trust company or a member of a
national securities exchange or of the National Association of Securities
Dealers, Inc.
<PAGE>
"Exercise Price" means $.01 per Warrant Share.
"Expiration Date" means the fourth anniversary of the date hereof at
5:00 p.m. New York City time.
"Investment Agreement" means the Investment Agreement dated as of
January 23, 1998 among the Company and the Shareholders listed on the signature
pages thereto, providing for the purchase and issuance of the Shares and this
Warrant.
"Person" means an individual, partnership, corporation, trust, joint
stock company, association, joint venture, or any other entity or organization,
including a government or political subdivision or an agency or instrumentality
thereof.
"Principal Holder" means the original Holder of this Warrant on the
date of issue, or if such original Holder so elects, any transferee of all or
any portion of this Warrant whom such original Holder shall have designated by
written notice to the Company as the successor Principal Holder. Any successor
Principal Holder designated pursuant to the immediately preceding sentence shall
also have the right upon any subsequent transfer to designate a successor
Principal Holder in the manner described above.
"Shareholders" means the Shareholders listed on the signature pages to
the Investment Agreement.
"Shares" means the shares of Common Stock purchased by the Shareholders
pursuant to the Investment Agreement.
"Warrant Shares" means the 210,655 shares of Common Stock deliverable
upon exercise of this Warrant, as adjusted from time to time.
(b) Capitalized terms used but not defined herein shall have the
meanings given them in the Investment Agreement.
2. Exercise of Warrant.
(a) The Holder is entitled to exercise this Warrant in whole or in
part at any time, or from time to time, until the Expiration Date or,
if such day is not a Business Day, then on the next succeeding day that
shall be a Business Day. To exercise this Warrant, the Holder shall
execute and deliver to the Company a Warrant Exercise Notice
substantially in the form annexed hereto. No earlier than ten days
after delivery of the Warrant Exercise Notice, the Holder shall deliver
to the Company this Warrant Certificate, including the Warrant Exercise
Subscription Form forming a part hereof duly executed by the Holder,
together with payment of the applicable Exercise Price. Upon such
delivery and payment, the Holder shall be deemed to be the holder of
record of the Warrant Shares subject to such exercise, notwithstanding
that the stock transfer books of the Company shall then be closed or
that certificates representing such Warrant Shares shall not then be
actually delivered to the Holder.
<PAGE>
(b) The Exercise Price may be paid in cash or by certified or official
bank check or bank cashier's check payable to the order of the Company
or by any combination of such cash or check. The Company shall pay any
and all documentary, stamp or similar issue or transfer taxes payable
in respect of the issue or delivery of the Warrant Shares.
(c) If the Holder exercises this Warrant in part, this Warrant
Certificate shall be surrendered by the Holder to the Company and a new
Warrant Certificate of the same tenor and for the unexercised number of
Warrant Shares shall be executed by the Company. The Company shall
register the new Warrant Certificate in the name of the Holder or in
such name or names of its transferee pursuant to paragraph 6 hereof as
may be directed in writing by the Holder and deliver the new Warrant
Certificate to the Person or Persons entitled to receive the same.
(d) Upon surrender of this Warrant Certificate in conformity with the
foregoing provisions, the Company shall transfer to the Holder of this
Warrant Certificate appropriate evidence of ownership of the shares of
Common Stock or other securities or property (including any money) to
which the Holder is entitled, registered or otherwise placed in, or
payable to the order of, the name or names of the Holder or such
transferee as may be directed in writing by the Holder, and shall
deliver such evidence of ownership and any other securities or property
(including any money) to the Person or Persons entitled to receive the
same, together with an amount in cash in lieu of any fraction of a
share as provided in paragraph 5 below.
3. Restrictive Legend. Certificates representing shares of Common
Stock issued pursuant to this Warrant shall bear a legend substantially in the
form of the legend set forth on the first page of this Warrant Certificate to
the extent that and for so long as such legend is required pursuant to the
Investment Agreement.
<PAGE>
4. Reservation of Shares. The Company hereby agrees that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of its authorized but unissued shares of Common Stock or other
securities of the Company from time to time issuable upon exercise of this
Warrant as will be sufficient to permit the exercise in full of this Warrant.
All such shares shall be duly authorized and, when issued upon such exercise,
shall be validly issued, fully paid and non-assessable, free and clear of all
liens, security interests, charges and other encumbrances or restrictions on
sale and free and clear of all preemptive rights, except to the extent set forth
in the Investment Agreement.
5. Fractional Shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant and in lieu
of delivery of any such fractional share upon any exercise hereof, the Company
shall pay to the Holder an amount in cash equal to such fraction multiplied by
the Current Market Price Per Common Share at the date of such exercise. For the
purpose of any computation under this paragraph 5, on any determination date the
Current Market Price Per Common Share shall be deemed to be the average
(weighted by daily trading volume) of the Daily Prices (as defined below) per
share of the applicable class of Common Stock for the 20 consecutive trading
days immediately prior to such date. "Daily Price" means (A) the last reported
sale price on such day if the Common Stock is listed on a national securities
exchange or admitted to unlisted trading privileges on such exchange or listed
for trading on the Nasdaq National Market; or (B) if the shares of such class of
Common Stock then are not so listed or admitted to unlisted trading privileges
but is traded on the Nasdaq Small Cap Market, the average of the closing bid and
asked prices for such day on such market and if the Common Stock is not so
traded, the current market value shall be the mean of the last reported bid and
asked prices reported by the National Quotation Bureau, Inc., on the last
business day prior to the determination date. If on any determination date the
shares of such class of Common Stock are not so listed or admitted to unlisted
trading privileges and bid and asked prices are not so reported, the Current
Market Price Per Common Share shall be the fair market value of such shares on
such determination date as determined by the Board of Directors. If the
Principal Holder shall object to any determination by the Board of Directors of
the Current Market Price Per Common Share, the Current Market Price Per Common
Share shall be the fair market value per share of the applicable class of Common
Stock as determined by an independent appraiser retained by the Company at its
expense and reasonably acceptable to the Principal Holder. For purposes of any
computation under this paragraph 5, the number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for
the account of the Company.
<PAGE>
6. Exchange, Transfer or Assignment of Warrant.
(a) This Warrant Certificate and all rights hereunder are not
transferable by the registered holder hereof except to any Person who,
prior to such transfer, agrees in writing, in form and substance
reasonably satisfactory to the Company, to be bound by the terms of the
Investment Agreement in accordance with the provisions thereof. Each
taker and holder of this Warrant Certificate by taking or holding the
same, consents and agrees that the registered holder hereof may be
treated by the Company and all other persons dealing with this Warrant
Certificate as the absolute owner hereof for any purpose and as the
person entitled to exercise the rights represented hereby.
(b) The Holder of this Warrant shall be entitled, without obtaining
the consent of the Company to assign and transfer this Warrant, at any
time in whole or from time to time in part, to any Person or Persons.
Subject to the preceding sentence, upon surrender of this Warrant to
the Company, together with the attached Warrant Assignment Form duly
executed, the Company shall, without charge, execute and deliver a new
Warrant in the name of the assignee or assignees named in such
instrument of assignment and, if the Holder's entire interest is not
being assigned, in the name of the Holder and this Warrant shall
promptly be canceled.
7. Loss or Destruction of Warrant. Upon receipt by the Company of
evidence satisfactory to it (in the exercise of its reasonable discretion) of
the loss, theft, destruction or mutilation of this Warrant Certificate, and (in
the case of loss, theft or destruction) of reasonably satisfactory
indemnification, and upon surrender and cancellation of this Warrant
Certificate, if mutilated, the Company shall execute and deliver a new Warrant
Certificate of like tenor and date.
8. Anti-dilution Provisions. In case the Company shall at any time
after the date hereof (i) declare a dividend or make a distribution on Common
Stock payable in Common Stock, (ii) subdivide or split the outstanding Common
Stock, (iii) combine or reclassify the outstanding Common Stock into a smaller
number of shares, or (iv) issue any shares of its capital stock in a
reclassification of Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), the number of Warrant Shares in effect at the time of the record
date for such dividend or distribution or of the effective date of such
subdivision, split, combination or reclassification shall be proportionately
adjusted so that the exercise of this Warrant after such time shall entitle the
holder to receive the aggregate number of shares of Common Stock or other
securities of the Company (or shares of any security into which such shares of
Common Stock have been reclassified pursuant to clause 8(a)(iii) or 8(a)(iv)
above) which, if this Warrant had been exercised immediately prior to such time,
such holder would have owned upon such exercise and been entitled to receive by
virtue of such dividend, distribution, subdivision, split, combination or
reclassification. An adjustment made pursuant to this Section 8(a) shall become
effective immediately after such record date in the case of a dividend or a
distribution and immediately after the effective date in the case of a
subdivision, split, combination or reclassification. Such adjustment shall be
made successively whenever any event listed above shall occur.
<PAGE>
9. Consolidation, Merger, or Sale of Assets. In case of any
consolidation of the Company with, or merger of the Company into, any other
Person, any merger of another Person into the Company (other than a merger which
does not result in any reclassification, conversion, exchange or cancellation of
outstanding shares of Common Stock) or any sale or transfer of all or
substantially all of the assets of the Company or of the Person formed by such
consolidation or resulting from such merger or which acquires such assets, as
the case may be, the Holder shall have the right thereafter to exercise this
Warrant for the kind and amount of securities, cash and other property
receivable upon such consolidation, merger, sale or transfer by a holder of the
number of shares of Common Stock for which this Warrant may have been exercised
immediately prior to such consolidation, merger, sale or transfer, assuming (i)
such holder of Common Stock is not a Person with which the Company consolidated
or into which the Company merged or which merged into the Company or to which
such sale or transfer was made, as the case may be ("constituent Person"), or an
Affiliate of a constituent Person and (ii) in the case of a consolidation,
merger, sale or transfer which includes an election as to the consideration to
be received by the holders, such holder of Common Stock failed to exercise its
rights of election, as to the kind or amount of securities, cash and other
property receivable upon such consolidation, merger, sale or transfer (provided
that if the kind or amount of securities, cash and other property receivable
upon such consolidation, merger, sale or transfer is not the same for each share
of Common Stock held immediately prior to such consolidation, merger, sale or
transfer by other than a constituent Person or an Affiliate thereof and in
respect of which such rights of election shall not have been exercised
("non-electing share"), then for the purpose of this paragraph 9, the kind and
amount of securities, cash and other property receivable upon such
consolidation, merger, sale or transfer by each non-electing share shall be
deemed to be the kind and amount so receivable per share by a plurality of the
non-electing shares). Adjustments for events subsequent to the effective date of
such a consolidation, merger and sale of assets shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Warrant. In any such
event, effective provisions shall be made in the certificate or articles of
incorporation of the resulting or surviving corporation, in any contract of
sale, conveyance, lease or transfer, or otherwise so that the provisions set
forth herein for the protection of the rights of the Holder shall thereafter
continue to be applicable; and any such resulting or surviving corporation shall
expressly assume the obligation to deliver, upon exercise, such shares of stock,
other securities, cash and property. The provisions of this paragraph 9 shall
similarly apply to successive consolidations, mergers, sales, leases or
transfers.
<PAGE>
10. Notices. Any notice, demand or delivery authorized by this Warrant
Certificate shall be in writing and shall be given to the Holder, the Company or
the Shareholder Representative, as the case may be, at its address (or
telecopier number) set forth below, or such other address (or telecopier number)
as shall have been furnished to the party giving or making such notice, demand
or delivery:
If to the Company:
IntegraMed America, Inc.
One Manhattanville Road
Purchase, New York 10577
Telecopy: (914) 253-8008
Attention: Gerardo Canet
If to the Holder:
Morgan Stanley Venture Partners
1221 Avenue of the Americas
New York, New York 10020
Telecopy: (212) 762-8424
Attention: M. Fazle Husain
Each such notice, demand or delivery shall be effective (i) if given by
telecopy, when such telecopy is transmitted to the telecopy number specified
herein and the intended recipient confirms the receipt of such telecopy or (ii)
if given by any other means, when received at the address specified herein.
11. Rights of the Holder. Prior to the exercise of any Warrant, the
Holder shall not, by virtue hereof, be entitled to any rights of a shareholder
of the Company, including, without limitation, the right to vote, to receive
dividends or other distributions, to exercise any preemptive right or to receive
any notice of meetings of shareholders or any notice of any proceedings of the
Company except as may be specifically provided for herein.
12. GOVERNING LAW. THIS WARRANT CERTIFICATE AND ALL RIGHTS ARISING
HEREUNDER SHALL BE CONSTRUED AND DETERMINED IN ACCORDANCE WITH THE INTERNAL LAWS
OF THE STATE OF NEW YORK, AND THE PERFORMANCE THEREOF SHALL BE GOVERNED AND
ENFORCED IN ACCORDANCE WITH SUCH LAWS.
<PAGE>
13. Amendments; Waivers. Any provision of this Warrant Certificate may
be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by the Holder and the Company, or in the
case of a waiver, by the party against whom the waiver is to be effective. No
failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by law.
<PAGE>
IN WITNESS WHEREOF, the Company has duly caused this Warrant
Certificate to be signed by its duly authorized officer and to be dated as of
January 23, 1998.
INTEGRAMED AMERICA, INC.
By: /s/ Dwight Ryan
----------------------------
Name: Dwight Ryan
Title: Chief Financial Officer
Acknowledged and Agreed:
MORGAN STANLEY VENTURE PARTNERS III, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
-------------------------
Name: M. Fazle Husain
Title: General Partner
<PAGE>
WARRANT EXERCISE NOTICE
(To be delivered prior to exercise of the Warrant
by execution of the Warrant Exercise Subscription Form)
To: IntegraMed America, Inc.
The undersigned hereby notifies you of its intention to exercise the
Warrant to purchase shares of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. The undersigned intends to exercise the Warrant to
purchase ___________ shares (the "Shares") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant). The undersigned intends to pay the
aggregate Exercise Price for the Shares in cash, certified or official bank or
bank cashier's check (or a combination of cash and check) as indicated below.
Date: __________________________
---------------------------------------------
(Signature of Owner)
---------------------------------------------
(Street Address)
---------------------------------------------
(City) (State)
Payment: $ ____________ cash
$ ____________ check
<PAGE>
WARRANT EXERCISE SUBSCRIPTION FORM
(To be executed only upon exercise of the Warrant
after deliver of Warrant Exercise Notice)
To: IntegraMed America, Inc.
The undersigned irrevocably exercises the Warrant for the purchase of
___________ shares (the "Shares") of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. (the "Company") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant) and herewith makes payment of
$___________ (such payment being made in cash or by certified or official bank
or bank cashier's check payable to the order of the Company or by any permitted
combination of such cash or check), all on the terms and conditions specified in
the within Warrant Certificate, surrenders this Warrant Certificate and all
right, title and interest therein to the Company and directs that the Shares
deliverable upon the exercise of this Warrant be registered or placed in the
name and at the address specified below and delivered thereto.
Date: ____________________________
-----------------------------------------
(Signature of Owner)
-----------------------------------------
(Street Address)
-----------------------------------------
(City) (State)
<PAGE>
Securities and/or check to be issued to: _______________________________________
Please insert social security or identifying number:____________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
Any unexercised portion of the Warrant evidenced by the within Warrant
Certificate to be issued to:
Please insert social security or identifying number: ___________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
<PAGE>
WARRANT ASSIGNMENT FORM
Dated ___________ ___, _____
FOR VALUE RECEIVED, _______________________ hereby sells,
assigns and transfers unto_____________________________(the "Assignee"),
(please type or print in block letters)
(insert address)
its right to purchase up to shares of Common Stock represented by this Warrant
and does hereby irrevocably constitute and appoint _______________________
Attorney, to transfer the same on the books of the Company, with full power of
substitution in the premises.
Signature:
INTEGRAMED AMERICA, INC.
WARRANT FOR THE PURCHASE OF SHARES OF
COMMON STOCK OF INTEGRAMED AMERICA, INC.
No. 2 Warrant to Purchase
Void after January 23, 2002 20,226 Shares
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD
EXCEPT IN COMPLIANCE THEREWITH.
FOR VALUE RECEIVED, INTEGRAMED AMERICA, INC., a Delaware corporation
(the "Company"), hereby certifies that Morgan Stanley Venture Investors III,
L.P., its successor or permitted assigns (the "Holder"), is entitled, subject to
the provisions of this Warrant, to purchase from the Company, at the times
specified herein, a number of fully paid and non-assessable shares of Common
Stock of the Company, par value $.01 per share (the "Common Stock"), equal to
the Warrant Shares (as hereinafter defined) at a purchase price per share equal
to the Exercise Price (as hereinafter defined). The number of Warrant Shares to
be received upon the exercise of this Warrant is subject to adjustment from time
to time as hereinafter set forth.
1. Definitions. (a) The following terms, as used herein, have the
following meanings:
"Affiliate" shall have the meaning given to such term in Rule 12b-2
promulgated under the Securities and Exchange Act of 1934, as amended.
"Business Day" means any day except a Saturday, Sunday or other day on
which commercial banks in the City of New York are authorized by law to close.
"Common Stock" means the Common Stock, par value $.01 per share, of
the Company.
<PAGE>
"Duly Endorsed" means duly endorsed in blank by the Person or Persons
in whose name a stock certificate is registered or accompanied by a duly
executed stock assignment separate from the certificate with the signature(s)
thereon guaranteed by a commercial bank or trust company or a member of a
national securities exchange or of the National Association of Securities
Dealers, Inc.
"Exercise Price" means $.01 per Warrant Share.
"Expiration Date" means the fourth anniversary of the date hereof at
5:00 p.m. New York City time.
"Investment Agreement" means the Investment Agreement dated as of
January 23, 1998 among the Company and the Shareholders listed on the signature
pages thereto, providing for the purchase and issuance of the Shares and this
Warrant.
"Person" means an individual, partnership, corporation, trust, joint
stock company, association, joint venture, or any other entity or organization,
including a government or political subdivision or an agency or instrumentality
thereof.
"Principal Holder" means the original Holder of this Warrant on the
date of issue, or if such original Holder so elects, any transferee of all or
any portion of this Warrant whom such original Holder shall have designated by
written notice to the Company as the successor Principal Holder. Any successor
Principal Holder designated pursuant to the immediately preceding sentence shall
also have the right upon any subsequent transfer to designate a successor
Principal Holder in the manner described above.
"Shareholders" means the Shareholders listed on the signature pages to
the Investment Agreement.
"Shares" means the shares of Common Stock purchased by the Shareholders
pursuant to the Investment Agreement.
"Warrant Shares" means the 20,226 shares of Common Stock deliverable
upon exercise of this Warrant, as adjusted from time to time.
(b) Capitalized terms used but not defined herein shall have the
meanings given them in the Investment Agreement.
<PAGE>
2. Exercise of Warrant.
(a) The Holder is entitled to exercise this Warrant in whole or in
part at any time, or from time to time, until the Expiration Date or,
if such day is not a Business Day, then on the next succeeding day that
shall be a Business Day. To exercise this Warrant, the Holder shall
execute and deliver to the Company a Warrant Exercise Notice
substantially in the form annexed hereto. No earlier than ten days
after delivery of the Warrant Exercise Notice, the Holder shall deliver
to the Company this Warrant Certificate, including the Warrant Exercise
Subscription Form forming a part hereof duly executed by the Holder,
together with payment of the applicable Exercise Price. Upon such
delivery and payment, the Holder shall be deemed to be the holder of
record of the Warrant Shares subject to such exercise, notwithstanding
that the stock transfer books of the Company shall then be closed or
that certificates representing such Warrant Shares shall not then be
actually delivered to the Holder.
(b) The Exercise Price may be paid in cash or by certified or official
bank check or bank cashier's check payable to the order of the Company
or by any combination of such cash or check. The Company shall pay any
and all documentary, stamp or similar issue or transfer taxes payable
in respect of the issue or delivery of the Warrant Shares.
(c) If the Holder exercises this Warrant in part, this Warrant
Certificate shall be surrendered by the Holder to the Company and a new
Warrant Certificate of the same tenor and for the unexercised number of
Warrant Shares shall be executed by the Company. The Company shall
register the new Warrant Certificate in the name of the Holder or in
such name or names of its transferee pursuant to paragraph 6 hereof as
may be directed in writing by the Holder and deliver the new Warrant
Certificate to the Person or Persons entitled to receive the same.
(d) Upon surrender of this Warrant Certificate in conformity with the
foregoing provisions, the Company shall transfer to the Holder of this
Warrant Certificate appropriate evidence of ownership of the shares of
Common Stock or other securities or property (including any money) to
which the Holder is entitled, registered or otherwise placed in, or
payable to the order of, the name or names of the Holder or such
transferee as may be directed in writing by the Holder, and shall
deliver such evidence of ownership and any other securities or property
(including any money) to the Person or Persons entitled to receive the
same, together with an amount in cash in lieu of any fraction of a
share as provided in paragraph 5 below.
<PAGE>
3. Restrictive Legend. Certificates representing shares of Common
Stock issued pursuant to this Warrant shall bear a legend substantially in the
form of the legend set forth on the first page of this Warrant Certificate to
the extent that and for so long as such legend is required pursuant to the
Investment Agreement.
4. Reservation of Shares. The Company hereby agrees that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of its authorized but unissued shares of Common Stock or other
securities of the Company from time to time issuable upon exercise of this
Warrant as will be sufficient to permit the exercise in full of this Warrant.
All such shares shall be duly authorized and, when issued upon such exercise,
shall be validly issued, fully paid and non-assessable, free and clear of all
liens, security interests, charges and other encumbrances or restrictions on
sale and free and clear of all preemptive rights, except to the extent set forth
in the Investment Agreement.
5. Fractional Shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant and in lieu
of delivery of any such fractional share upon any exercise hereof, the Company
shall pay to the Holder an amount in cash equal to such fraction multiplied by
the Current Market Price Per Common Share at the date of such exercise. For the
purpose of any computation under this paragraph 5, on any determination date the
Current Market Price Per Common Share shall be deemed to be the average
(weighted by daily trading volume) of the Daily Prices (as defined below) per
share of the applicable class of Common Stock for the 20 consecutive trading
days immediately prior to such date. "Daily Price" means (A) the last reported
sale price on such day if the Common Stock is listed on a national securities
exchange or admitted to unlisted trading privileges on such exchange or listed
for trading on the Nasdaq National Market; or (B) if the shares of such class of
Common Stock then are not so listed or admitted to unlisted trading privileges
but is traded on the Nasdaq Small Cap Market, the average of the closing bid and
asked prices for such day on such market and if the Common Stock is not so
traded, the current market value shall be the mean of the last reported bid and
asked prices reported by the National Quotation Bureau, Inc., on the last
business day prior to the determination date. If on any determination date the
shares of such class of Common Stock are not so listed or admitted to unlisted
trading privileges and bid and asked prices are not so reported, the Current
Market Price Per Common Share shall be the fair market value of such shares on
such determination date as determined by the Board of Directors. If the
Principal Holder shall object to any determination by the Board of Directors of
the Current Market Price Per Common Share, the Current Market Price Per Common
Share shall be the fair market value per share of the applicable class of Common
Stock as determined by an independent appraiser retained by the Company at its
expense and reasonably acceptable to the Principal Holder. For purposes of any
computation under this paragraph 5, the number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for
the account of the Company.
<PAGE>
6. Exchange, Transfer or Assignment of Warrant.
(a) This Warrant Certificate and all rights hereunder are not
transferable by the registered holder hereof except to any Person who,
prior to such transfer, agrees in writing, in form and substance
reasonably satisfactory to the Company, to be bound by the terms of the
Investment Agreement in accordance with the provisions thereof. Each
taker and holder of this Warrant Certificate by taking or holding the
same, consents and agrees that the registered holder hereof may be
treated by the Company and all other persons dealing with this Warrant
Certificate as the absolute owner hereof for any purpose and as the
person entitled to exercise the rights represented hereby.
(b) The Holder of this Warrant shall be entitled, without obtaining
the consent of the Company to assign and transfer this Warrant, at any
time in whole or from time to time in part, to any Person or Persons.
Subject to the preceding sentence, upon surrender of this Warrant to
the Company, together with the attached Warrant Assignment Form duly
executed, the Company shall, without charge, execute and deliver a new
Warrant in the name of the assignee or assignees named in such
instrument of assignment and, if the Holder's entire interest is not
being assigned, in the name of the Holder and this Warrant shall
promptly be canceled.
7. Loss or Destruction of Warrant. Upon receipt by the Company of
evidence satisfactory to it (in the exercise of its reasonable discretion) of
the loss, theft, destruction or mutilation of this Warrant Certificate, and (in
the case of loss, theft or destruction) of reasonably satisfactory
indemnification, and upon surrender and cancellation of this Warrant
Certificate, if mutilated, the Company shall execute and deliver a new Warrant
Certificate of like tenor and date.
<PAGE>
8. Anti-dilution Provisions. In case the Company shall at any time
after the date hereof (i) declare a dividend or make a distribution on Common
Stock payable in Common Stock, (ii) subdivide or split the outstanding Common
Stock, (iii) combine or reclassify the outstanding Common Stock into a smaller
number of shares, or (iv) issue any shares of its capital stock in a
reclassification of Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), the number of Warrant Shares in effect at the time of the record
date for such dividend or distribution or of the effective date of such
subdivision, split, combination or reclassification shall be proportionately
adjusted so that the exercise of this Warrant after such time shall entitle the
holder to receive the aggregate number of shares of Common Stock or other
securities of the Company (or shares of any security into which such shares of
Common Stock have been reclassified pursuant to clause 8(a)(iii) or 8(a)(iv)
above) which, if this Warrant had been exercised immediately prior to such time,
such holder would have owned upon such exercise and been entitled to receive by
virtue of such dividend, distribution, subdivision, split, combination or
reclassification. An adjustment made pursuant to this Section 8(a) shall become
effective immediately after such record date in the case of a dividend or a
distribution and immediately after the effective date in the case of a
subdivision, split, combination or reclassification. Such adjustment shall be
made successively whenever any event listed above shall occur.
9. Consolidation, Merger, or Sale of Assets. In case of any
consolidation of the Company with, or merger of the Company into, any other
Person, any merger of another Person into the Company (other than a merger which
does not result in any reclassification, conversion, exchange or cancellation of
outstanding shares of Common Stock) or any sale or transfer of all or
substantially all of the assets of the Company or of the Person formed by such
consolidation or resulting from such merger or which acquires such assets, as
the case may be, the Holder shall have the right thereafter to exercise this
Warrant for the kind and amount of securities, cash and other property
receivable upon such consolidation, merger, sale or transfer by a holder of the
number of shares of Common Stock for which this Warrant may have been exercised
immediately prior to such consolidation, merger, sale or transfer, assuming (i)
such holder of Common Stock is not a Person with which the Company consolidated
or into which the Company merged or which merged into the Company or to which
such sale or transfer was made, as the case may be ("constituent Person"), or an
Affiliate of a constituent Person and (ii) in the case of a consolidation,
merger, sale or transfer which includes an election as to the consideration to
be received by the holders, such holder of Common Stock failed to exercise its
rights of election, as to the kind or amount of securities, cash and other
property receivable upon such consolidation, merger, sale or transfer (provided
that if the kind or amount of securities, cash and other property receivable
upon such consolidation, merger, sale or transfer is not the same for each share
of Common Stock held immediately prior to such consolidation, merger, sale or
transfer by other than a constituent Person or an Affiliate thereof and in
respect of which such rights of election shall not have been exercised
("non-electing share"), then for the purpose of this paragraph 9, the kind and
amount of securities, cash and other property receivable upon such
consolidation, merger, sale or transfer by each non-electing share shall be
deemed to be the kind and amount so receivable per share by a plurality of the
non-electing shares). Adjustments for events subsequent to the effective date of
such a consolidation, merger and sale of assets shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Warrant. In any such
event, effective provisions shall be made in the certificate or articles of
incorporation of the resulting or surviving corporation, in any contract of
sale, conveyance, lease or transfer, or otherwise so that the provisions set
forth herein for the protection of the rights of the Holder shall thereafter
continue to be applicable; and any such resulting or surviving corporation shall
expressly assume the obligation to deliver, upon exercise, such shares of stock,
other securities, cash and property. The provisions of this paragraph 9 shall
similarly apply to successive consolidations, mergers, sales, leases or
transfers.
<PAGE>
10. Notices. Any notice, demand or delivery authorized by this Warrant
Certificate shall be in writing and shall be given to the Holder, the Company or
the Shareholder Representative, as the case may be, at its address (or
telecopier number) set forth below, or such other address (or telecopier number)
as shall have been furnished to the party giving or making such notice, demand
or delivery:
If to the Company:
IntegraMed America, Inc.
One Manhattanville Road
Purchase, New York 10577
Telecopy: (914) 253-8008
Attention: Gerardo Canet
If to the Holder:
Morgan Stanley Venture Partners
1221 Avenue of the Americas
New York, New York 10020
Telecopy: (212) 762-8424
Attention: M. Fazle Husain
Each such notice, demand or delivery shall be effective (i) if given by
telecopy, when such telecopy is transmitted to the telecopy number specified
herein and the intended recipient confirms the receipt of such telecopy or (ii)
if given by any other means, when received at the address specified herein.
<PAGE>
11. Rights of the Holder. Prior to the exercise of any Warrant, the
Holder shall not, by virtue hereof, be entitled to any rights of a shareholder
of the Company, including, without limitation, the right to vote, to receive
dividends or other distributions, to exercise any preemptive right or to receive
any notice of meetings of shareholders or any notice of any proceedings of the
Company except as may be specifically provided for herein.
12. GOVERNING LAW. THIS WARRANT CERTIFICATE AND ALL RIGHTS ARISING
HEREUNDER SHALL BE CONSTRUED AND DETERMINED IN ACCORDANCE WITH THE INTERNAL LAWS
OF THE STATE OF NEW YORK, AND THE PERFORMANCE THEREOF SHALL BE GOVERNED AND
ENFORCED IN ACCORDANCE WITH
SUCH LAWS.
13. Amendments; Waivers. Any provision of this Warrant Certificate may
be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by the Holder and the Company, or in the
case of a waiver, by the party against whom the waiver is to be effective. No
failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by law.
<PAGE>
IN WITNESS WHEREOF, the Company has duly caused this Warrant
Certificate to be signed by its duly authorized officer and to be dated as of
January 23, 1998.
INTEGRAMED AMERICA, INC.
By: /s/ Dwight Ryan
--------------------------------
Name: Dwight Ryan
Title: Chief Financial Officer
Acknowledged and Agreed:
MORGAN STANLEY VENTURE INVESTORS III, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
-------------------------------------
Name: M. Fazle Husain
Title: General Partner
<PAGE>
WARRANT EXERCISE NOTICE
(To be delivered prior to exercise of the Warrant
by execution of the Warrant Exercise Subscription Form)
To: IntegraMed America, Inc.
The undersigned hereby notifies you of its intention to exercise the
Warrant to purchase shares of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. The undersigned intends to exercise the Warrant to
purchase ___________ shares (the "Shares") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant). The undersigned intends to pay the
aggregate Exercise Price for the Shares in cash, certified or official bank or
bank cashier's check (or a combination of cash and check) as indicated below.
Date: __________________________
---------------------------------------------
(Signature of Owner)
---------------------------------------------
(Street Address)
---------------------------------------------
(City) (State)
Payment: $ ____________ cash
$ ____________ check
<PAGE>
WARRANT EXERCISE SUBSCRIPTION FORM
(To be executed only upon exercise of the Warrant
after deliver of Warrant Exercise Notice)
To: IntegraMed America, Inc.
The undersigned irrevocably exercises the Warrant for the purchase of
___________ shares (the "Shares") of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. (the "Company") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant) and herewith makes payment of
$___________ (such payment being made in cash or by certified or official bank
or bank cashier's check payable to the order of the Company or by any permitted
combination of such cash or check), all on the terms and conditions specified in
the within Warrant Certificate, surrenders this Warrant Certificate and all
right, title and interest therein to the Company and directs that the Shares
deliverable upon the exercise of this Warrant be registered or placed in the
name and at the address specified below and delivered thereto.
Date: ____________________________
-----------------------------------------
(Signature of Owner)
-----------------------------------------
(Street Address)
-----------------------------------------
(City) (State)
<PAGE>
Securities and/or check to be issued to: _______________________________________
Please insert social security or identifying number:____________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
Any unexercised portion of the Warrant evidenced by the within Warrant
Certificate to be issued to:
Please insert social security or identifying number: ___________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
<PAGE>
WARRANT ASSIGNMENT FORM
Dated ___________ ___, _____
FOR VALUE RECEIVED, _______________________ hereby sells,
assigns and transfers unto_____________________________(the "Assignee"),
(please type or print in block letters)
(insert address)
its right to purchase up to shares of Common Stock represented by this Warrant
and does hereby irrevocably constitute and appoint _______________________
Attorney, to transfer the same on the books of the Company, with full power of
substitution in the premises.
Signature:
INTEGRAMED AMERICA, INC.
WARRANT FOR THE PURCHASE OF SHARES OF
COMMON STOCK OF INTEGRAMED AMERICA, INC.
No. 3 Warrant to Purchase
Void after January 23, 2002 9,119 Shares
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD
EXCEPT IN COMPLIANCE THEREWITH.
FOR VALUE RECEIVED, INTEGRAMED AMERICA, INC., a
Delaware corporation (the "Company"), hereby certifies that The Morgan Stanley
Venture Partners Entrepreneur Fund, L.P., its successor or permitted assigns
(the "Holder"), is entitled, subject to the provisions of this Warrant, to
purchase from the Company, at the times specified herein, a number of fully paid
and non-assessable shares of Common Stock of the Company, par value $.01 per
share (the "Common Stock"), equal to the Warrant Shares (as hereinafter defined)
at a purchase price per share equal to the Exercise Price (as hereinafter
defined). The number of Warrant Shares to be received upon the exercise of this
Warrant is subject to adjustment from time to time as hereinafter set forth.
1. Definitions. (a) The following terms, as used herein, have the
following meanings:
"Affiliate" shall have the meaning given to such term in Rule 12b-2
promulgated under the Securities and Exchange Act of 1934, as amended.
"Business Day" means any day except a Saturday, Sunday or other day on
which commercial banks in the City of New York are authorized by law to close.
"Common Stock" means the Common Stock, par value $.01 per share, of
the Company.
<PAGE>
"Duly Endorsed" means duly endorsed in blank by the Person or Persons
in whose name a stock certificate is registered or accompanied by a duly
executed stock assignment separate from the certificate with the signature(s)
thereon guaranteed by a commercial bank or trust company or a member of a
national securities exchange or of the National Association of Securities
Dealers, Inc.
"Exercise Price" means $.01 per Warrant Share.
"Expiration Date" means the fourth anniversary of the date hereof at
5:00 p.m. New York City time.
"Investment Agreement" means the Investment Agreement dated as of
January 23, 1998 among the Company and the Shareholders listed on the signature
pages thereto, providing for the purchase and issuance of the Shares and this
Warrant.
"Person" means an individual, partnership, corporation, trust, joint
stock company, association, joint venture, or any other entity or organization,
including a government or political subdivision or an agency or instrumentality
thereof.
"Principal Holder" means the original Holder of this Warrant on the
date of issue, or if such original Holder so elects, any transferee of all or
any portion of this Warrant whom such original Holder shall have designated by
written notice to the Company as the successor Principal Holder. Any successor
Principal Holder designated pursuant to the immediately preceding sentence shall
also have the right upon any subsequent transfer to designate a successor
Principal Holder in the manner described above.
"Shareholders" means the Shareholders listed on the signature pages to
the Investment Agreement.
"Shares" means the shares of Common Stock purchased by the Shareholders
pursuant to the Investment Agreement.
"Warrant Shares" means the 9,119 shares of Common Stock deliverable
upon exercise of this Warrant, as adjusted from time to time.
(b) Capitalized terms used but not defined herein shall have the
meanings given them in the Investment Agreement.
<PAGE>
2. Exercise of Warrant.
(a) The Holder is entitled to exercise this Warrant in whole or in
part at any time, or from time to time, until the Expiration Date or,
if such day is not a Business Day, then on the next succeeding day that
shall be a Business Day. To exercise this Warrant, the Holder shall
execute and deliver to the Company a Warrant Exercise Notice
substantially in the form annexed hereto. No earlier than ten days
after delivery of the Warrant Exercise Notice, the Holder shall deliver
to the Company this Warrant Certificate, including the Warrant Exercise
Subscription Form forming a part hereof duly executed by the Holder,
together with payment of the applicable Exercise Price. Upon such
delivery and payment, the Holder shall be deemed to be the holder of
record of the Warrant Shares subject to such exercise, notwithstanding
that the stock transfer books of the Company shall then be closed or
that certificates representing such Warrant Shares shall not then be
actually delivered to the Holder.
(b) The Exercise Price may be paid in cash or by certified or official
bank check or bank cashier's check payable to the order of the Company
or by any combination of such cash or check. The Company shall pay any
and all documentary, stamp or similar issue or transfer taxes payable
in respect of the issue or delivery of the Warrant Shares.
(c) If the Holder exercises this Warrant in part, this Warrant
Certificate shall be surrendered by the Holder to the Company and a new
Warrant Certificate of the same tenor and for the unexercised number of
Warrant Shares shall be executed by the Company. The Company shall
register the new Warrant Certificate in the name of the Holder or in
such name or names of its transferee pursuant to paragraph 6 hereof as
may be directed in writing by the Holder and deliver the new Warrant
Certificate to the Person or Persons entitled to receive the same.
(d) Upon surrender of this Warrant Certificate in conformity with the
foregoing provisions, the Company shall transfer to the Holder of this
Warrant Certificate appropriate evidence of ownership of the shares of
Common Stock or other securities or property (including any money) to
which the Holder is entitled, registered or otherwise placed in, or
payable to the order of, the name or names of the Holder or such
transferee as may be directed in writing by the Holder, and shall
deliver such evidence of ownership and any other securities or property
(including any money) to the Person or Persons entitled to receive the
same, together with an amount in cash in lieu of any fraction of a
share as provided in paragraph 5 below.
<PAGE>
3. Restrictive Legend. Certificates representing shares of Common
Stock issued pursuant to this Warrant shall bear a legend substantially in the
form of the legend set forth on the first page of this Warrant Certificate to
the extent that and for so long as such legend is required pursuant to the
Investment Agreement.
4. Reservation of Shares. The Company hereby agrees that at all times
there shall be reserved for issuance and delivery upon exercise of this Warrant
such number of its authorized but unissued shares of Common Stock or other
securities of the Company from time to time issuable upon exercise of this
Warrant as will be sufficient to permit the exercise in full of this Warrant.
All such shares shall be duly authorized and, when issued upon such exercise,
shall be validly issued, fully paid and non-assessable, free and clear of all
liens, security interests, charges and other encumbrances or restrictions on
sale and free and clear of all preemptive rights, except to the extent set forth
in the Investment Agreement.
5. Fractional Shares. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant and in lieu
of delivery of any such fractional share upon any exercise hereof, the Company
shall pay to the Holder an amount in cash equal to such fraction multiplied by
the Current Market Price Per Common Share at the date of such exercise. For the
purpose of any computation under this paragraph 5, on any determination date the
Current Market Price Per Common Share shall be deemed to be the average
(weighted by daily trading volume) of the Daily Prices (as defined below) per
share of the applicable class of Common Stock for the 20 consecutive trading
days immediately prior to such date. "Daily Price" means (A) the last reported
sale price on such day if the Common Stock is listed on a national securities
exchange or admitted to unlisted trading privileges on such exchange or listed
for trading on the Nasdaq National Market; or (B) if the shares of such class of
Common Stock then are not so listed or admitted to unlisted trading privileges
but is traded on the Nasdaq Small Cap Market, the average of the closing bid and
asked prices for such day on such market and if the Common Stock is not so
traded, the current market value shall be the mean of the last reported bid and
asked prices reported by the National Quotation Bureau, Inc., on the last
business day prior to the determination date. If on any determination date the
shares of such class of Common Stock are not so listed or admitted to unlisted
trading privileges and bid and asked prices are not so reported, the Current
Market Price Per Common Share shall be the fair market value of such shares on
such determination date as determined by the Board of Directors. If the
Principal Holder shall object to any determination by the Board of Directors of
the Current Market Price Per Common Share, the Current Market Price Per Common
Share shall be the fair market value per share of the applicable class of Common
Stock as determined by an independent appraiser retained by the Company at its
expense and reasonably acceptable to the Principal Holder. For purposes of any
computation under this paragraph 5, the number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or for
the account of the Company.
<PAGE>
6. Exchange, Transfer or Assignment of Warrant.
(a) This Warrant Certificate and all rights hereunder are not
transferable by the registered holder hereof except to any Person who,
prior to such transfer, agrees in writing, in form and substance
reasonably satisfactory to the Company, to be bound by the terms of the
Investment Agreement in accordance with the provisions thereof. Each
taker and holder of this Warrant Certificate by taking or holding the
same, consents and agrees that the registered holder hereof may be
treated by the Company and all other persons dealing with this Warrant
Certificate as the absolute owner hereof for any purpose and as the
person entitled to exercise the rights represented hereby.
(b) The Holder of this Warrant shall be entitled, without obtaining
the consent of the Company to assign and transfer this Warrant, at any
time in whole or from time to time in part, to any Person or Persons.
Subject to the preceding sentence, upon surrender of this Warrant to
the Company, together with the attached Warrant Assignment Form duly
executed, the Company shall, without charge, execute and deliver a new
Warrant in the name of the assignee or assignees named in such
instrument of assignment and, if the Holder's entire interest is not
being assigned, in the name of the Holder and this Warrant shall
promptly be canceled.
7. Loss or Destruction of Warrant. Upon receipt by the Company of
evidence satisfactory to it (in the exercise of its reasonable discretion) of
the loss, theft, destruction or mutilation of this Warrant Certificate, and (in
the case of loss, theft or destruction) of reasonably satisfactory
indemnification, and upon surrender and cancellation of this Warrant
Certificate, if mutilated, the Company shall execute and deliver a new Warrant
Certificate of like tenor and date.
8. Anti-dilution Provisions. In case the Company shall at any time
after the date hereof (i) declare a dividend or make a distribution on Common
Stock payable in Common Stock, (ii) subdivide or split the outstanding Common
Stock, (iii) combine or reclassify the outstanding Common Stock into a smaller
number of shares, or (iv) issue any shares of its capital stock in a
reclassification of Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), the number of Warrant Shares in effect at the time of the record
date for such dividend or distribution or of the effective date of such
subdivision, split, combination or reclassification shall be proportionately
adjusted so that the exercise of this Warrant after such time shall entitle the
holder to receive the aggregate number of shares of Common Stock or other
securities of the Company (or shares of any security into which such shares of
Common Stock have been reclassified pursuant to clause 8(a)(iii) or 8(a)(iv)
above) which, if this Warrant had been exercised immediately prior to such time,
such holder would have owned upon such exercise and been entitled to receive by
virtue of such dividend, distribution, subdivision, split, combination or
reclassification. An adjustment made pursuant to this Section 8(a) shall become
effective immediately after such record date in the case of a dividend or a
distribution and immediately after the effective date in the case of a
subdivision, split, combination or reclassification. Such adjustment shall be
made successively whenever any event listed above shall occur.
<PAGE>
9. Consolidation, Merger, or Sale of Assets. In case of any
consolidation of the Company with, or merger of the Company into, any other
Person, any merger of another Person into the Company (other than a merger which
does not result in any reclassification, conversion, exchange or cancellation of
outstanding shares of Common Stock) or any sale or transfer of all or
substantially all of the assets of the Company or of the Person formed by such
consolidation or resulting from such merger or which acquires such assets, as
the case may be, the Holder shall have the right thereafter to exercise this
Warrant for the kind and amount of securities, cash and other property
receivable upon such consolidation, merger, sale or transfer by a holder of the
number of shares of Common Stock for which this Warrant may have been exercised
immediately prior to such consolidation, merger, sale or transfer, assuming (i)
such holder of Common Stock is not a Person with which the Company consolidated
or into which the Company merged or which merged into the Company or to which
such sale or transfer was made, as the case may be ("constituent Person"), or an
Affiliate of a constituent Person and (ii) in the case of a consolidation,
merger, sale or transfer which includes an election as to the consideration to
be received by the holders, such holder of Common Stock failed to exercise its
rights of election, as to the kind or amount of securities, cash and other
property receivable upon such consolidation, merger, sale or transfer (provided
that if the kind or amount of securities, cash and other property receivable
upon such consolidation, merger, sale or transfer is not the same for each share
of Common Stock held immediately prior to such consolidation, merger, sale or
transfer by other than a constituent Person or an Affiliate thereof and in
respect of which such rights of election shall not have been exercised
("non-electing share"), then for the purpose of this paragraph 9, the kind and
amount of securities, cash and other property receivable upon such
consolidation, merger, sale or transfer by each non-electing share shall be
deemed to be the kind and amount so receivable per share by a plurality of the
non-electing shares). Adjustments for events subsequent to the effective date of
such a consolidation, merger and sale of assets shall be as nearly equivalent as
may be practicable to the adjustments provided for in this Warrant. In any such
event, effective provisions shall be made in the certificate or articles of
incorporation of the resulting or surviving corporation, in any contract of
sale, conveyance, lease or transfer, or otherwise so that the provisions set
forth herein for the protection of the rights of the Holder shall thereafter
continue to be applicable; and any such resulting or surviving corporation shall
expressly assume the obligation to deliver, upon exercise, such shares of stock,
other securities, cash and property. The provisions of this paragraph 9 shall
similarly apply to successive consolidations, mergers, sales, leases or
transfers.
<PAGE>
10. Notices. Any notice, demand or delivery authorized by this Warrant
Certificate shall be in writing and shall be given to the Holder, the Company or
the Shareholder Representative, as the case may be, at its address (or
telecopier number) set forth below, or such other address (or telecopier number)
as shall have been furnished to the party giving or making such notice, demand
or delivery:
If to the Company:
IntegraMed America, Inc.
One Manhattanville Road
Purchase, New York 10577
Telecopy: (914) 253-8008
Attention: Gerardo Canet
If to the Holder:
Morgan Stanley Venture Partners
1221 Avenue of the Americas
New York, New York 10020
Telecopy: (212) 762-8424
Attention: M. Fazle Husain
Each such notice, demand or delivery shall be effective (i) if given by
telecopy, when such telecopy is transmitted to the telecopy number specified
herein and the intended recipient confirms the receipt of such telecopy or (ii)
if given by any other means, when received at the address specified herein.
<PAGE>
11. Rights of the Holder. Prior to the exercise of any Warrant, the
Holder shall not, by virtue hereof, be entitled to any rights of a shareholder
of the Company, including, without limitation, the right to vote, to receive
dividends or other distributions, to exercise any preemptive right or to receive
any notice of meetings of shareholders or any notice of any proceedings of the
Company except as may be specifically provided for herein.
12. GOVERNING LAW. THIS WARRANT CERTIFICATE AND ALL RIGHTS ARISING
HEREUNDER SHALL BE CONSTRUED AND DETERMINED IN ACCORDANCE WITH THE INTERNAL LAWS
OF THE STATE OF NEW YORK, AND THE PERFORMANCE THEREOF SHALL BE GOVERNED AND
ENFORCED IN ACCORDANCE WITH
SUCH LAWS.
13. Amendments; Waivers. Any provision of this Warrant Certificate may
be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by the Holder and the Company, or in the
case of a waiver, by the party against whom the waiver is to be effective. No
failure or delay by either party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. The rights and remedies herein provided
shall be cumulative and not exclusive of any rights or remedies provided by law.
<PAGE>
IN WITNESS WHEREOF, the Company has duly caused this Warrant
Certificate to be signed by its duly authorized officer and to be dated as of
January 23, 1998.
INTEGRAMED AMERICA, INC.
By: /s/ Dwight Ryan
-------------------------------
Name: Dwight Ryan
Title: Chief Financial Officer
Acknowledged and Agreed:
THE MORGAN STANLEY VENTURE
PARTNERS ENTREPRENEUR FUND, L.P.
By: Morgan Stanley Venture Partners III, L.L.C.
its General Partner
By: Morgan Stanley Venture Capital III, Inc.,
its Institutional Managing Member
By: /s/ M. Fazle Husain
--------------------------------
Name: M. Fazle Husain
Title: General Partner
<PAGE>
WARRANT EXERCISE NOTICE
(To be delivered prior to exercise of the Warrant
by execution of the Warrant Exercise Subscription Form)
To: IntegraMed America, Inc.
The undersigned hereby notifies you of its intention to exercise the
Warrant to purchase shares of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. The undersigned intends to exercise the Warrant to
purchase ___________ shares (the "Shares") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant). The undersigned intends to pay the
aggregate Exercise Price for the Shares in cash, certified or official bank or
bank cashier's check (or a combination of cash and check) as indicated below.
Date: __________________________
---------------------------------------------
(Signature of Owner)
---------------------------------------------
(Street Address)
---------------------------------------------
(City) (State)
Payment: $ ____________ cash
$ ____________ check
<PAGE>
WARRANT EXERCISE SUBSCRIPTION FORM
(To be executed only upon exercise of the Warrant
after deliver of Warrant Exercise Notice)
To: IntegraMed America, Inc.
The undersigned irrevocably exercises the Warrant for the purchase of
___________ shares (the "Shares") of Common Stock, par value $.01 per share, of
IntegraMed America, Inc. (the "Company") at $.01 per Share (the Exercise Price
currently in effect pursuant to the Warrant) and herewith makes payment of
$___________ (such payment being made in cash or by certified or official bank
or bank cashier's check payable to the order of the Company or by any permitted
combination of such cash or check), all on the terms and conditions specified in
the within Warrant Certificate, surrenders this Warrant Certificate and all
right, title and interest therein to the Company and directs that the Shares
deliverable upon the exercise of this Warrant be registered or placed in the
name and at the address specified below and delivered thereto.
Date: ____________________________
-----------------------------------------
(Signature of Owner)
-----------------------------------------
(Street Address)
-----------------------------------------
(City) (State)
<PAGE>
Securities and/or check to be issued to: _______________________________________
Please insert social security or identifying number:____________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
Any unexercised portion of the Warrant evidenced by the within Warrant
Certificate to be issued to:
Please insert social security or identifying number: ___________________________
Name: __________________________________________________________________________
Street Address: ________________________________________________________________
City, State and Zip Code: ______________________________________________________
<PAGE>
WARRANT ASSIGNMENT FORM
Dated ___________ ___, _____
FOR VALUE RECEIVED, _______________________ hereby sells,
assigns and transfers unto_____________________________(the "Assignee"),
(please type or print in block letters)
(insert address)
its right to purchase up to shares of Common Stock represented by this Warrant
and does hereby irrevocably constitute and appoint _______________________
Attorney, to transfer the same on the books of the Company, with full power of
substitution in the premises.
Signature:
Dwight Ryan Noonan/Russo Communications, Inc.
Vice President and (212) 696-4455
Chief Financial Officer Heather Hennessy (media) ext. 274
IntegraMed America Jessica Livingston (investor) ext. 229
(914) 253-8000 ext. 243 e-mail: [email protected]
INTEGRAMED AMERICA ANNOUNCES A PROPOSED MANAGEMENT CONTRACT
WITH SHADY GROVE FERTILITY CENTERS, INC.
- The Company Announces A Financing By Morgan Stanley Venture Partners -
Purchase, NY, January 26, 1998 - IntegraMed America, Inc. (Nasdaq: INMD) today
announced it signed a letter of intent providing for the purchase by the Company
of Shady Grove Fertility Centers, Inc. ("SGFC") and a long-term management
agreement with its shareholders. This transaction, expected to close in February
1998, will be the second significant acquisition and fourth management agreement
that IntegraMed America has completed in the last five months. In addition,
IntegraMed America also announced that it closed on an equity private placement
of $5.5 million with Morgan Stanley Venture Partners III, L.P., the venture
capital affiliate of Morgan Stanley, Dean Witter, Discover & Co. (NYSE: MWD)
providing for the purchase of 3,235,294 shares of Common Stock at a price of
$1.70 per share and 240,000 Warrants to purchase shares of Common Stock, at a
nominal exercise price.
SGFC's physician group practice, located in the
Maryland/Washington/NorthernVirginia area, is one of the leading infertility
providers in the country. The group provides a full range of infertility
services including in vitro fertilization, intracytoplasmic sperm injection,
embryo cryopreservation, assisted hatching, egg donation and other assisted
reproductive technologies (ART) services. With four locations in the
Maryland/Washington/Northern Virginia area, the group practice has developed an
effective strategy to concentrate high cost ART services in a single location
while covering an extended geographic area in one of the largest and most
important ART markets in the country.
Led by Michael J. Levy, MD; Arthur W. Sagoskin, MD; and Robert J. Stillman, MD,
SGFC was founded in 1982 and has since grown over the years through mergers of
medical practices, the most recent of which was with Robert J. Stillman, MD in
April 1997. "We decided to affiliate with IntegraMed America's network based on
its reputation of managing medical practices which offer the highest quality of
care, as well as its commitment to provide these practices with cutting edge
technology and reduced costs," said Michael Levy, MD.
In 1997, SGFC had unaudited clinical revenues of approximately $7.2 million.
Based on the terms of the transaction, which provide that the Company's
management fees will be comprised of reimbursed costs of services and a fixed
percentage of revenues, plus an additional variable percentage of SGFC's
revenues, it is anticipated that SGFC will have a positive impact on the
Company's results of operations.
<PAGE>
"We are looking forward to having SGFC as a part of our growing network of
physicians," said Gerardo Canet, President and Chief Executive Officer of
IntegraMed America. "This acquisition increases our geographic reach in the
Maryland/Washington/Northern Virginia area and follows our strategy of
developing physician group practices in major market areas. Morgan Stanley's
investment significantly strengthens our financial position and we believe that
their participation as an investor reinforces our position as a leader in the
infertility industry."
Fazle Husain, General Partner of Morgan Stanley Venture Partners, said today,
"Our extensive research in the infertility industry demonstrated the growth
potential of this niche market. IntegraMed America is a leading practice
management company in the industry, and its strong leadership and aggressive
business plans make it an exciting investment for us."
IntegraMed America, based in Purchase, New York, is the largest physician
practice management company specializing in infertility and ART services. The
Company facilitates growth and development of its Network sites through access
to clinical, management, marketing and capital support. The Company manages 10
reproductive sciences Network sites in eight states and the District of
Columbia. Currently, there are approximately 6.1 million infertile couples in
the United States, totaling a $1 billion U.S. infertility market.
####
Statements contained in this press release that are not based on historical
fact, including statements regarding revenues and future expansion of IntegraMed
America, are forward-looking statements. Actual results may differ materially
from the statements made as a result of various factors including, but not
limited to, the risks associated with the Company's ability to finance future
growth; the loss of significant management contract(s); profitability at Network
sites managed by IntegraMed America; changes in insurance coverage, government
laws and regulations regarding health care or managed care contracting and other
risks, including those identified in the Company's most recent Form 10-K and in
other documents filed by the Company with the U.S. Securities and Exchange
Commission (SEC).
Editor's Notes:
This release is available on the Internet at http://www.noonanrusso.com.
